Johnson & Johnson (JNJ) 10-Q 29 Apr 20 2020 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 29, 2020	Apr. 22, 2020
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 29, 2020
Document Transition Report	false
Entity File Number	1-3215
Entity Registrant Name	Johnson & Johnson
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,634,594,535
Entity Central Index Key	0000200406
Current Fiscal Year End Date	--01-03
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Common Stock, Par Value $1.00
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.250% Notes Due January 2022
Entity Information [Line Items]
Title of 12(b) Security	0.250% Notes Due January 2022
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Entity Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Entity Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Entity Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Entity Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 29, 2020	Dec. 29, 2019
Current assets:
Cash and cash equivalents	$ 15,530	$ 17,305
Marketable securities	2,494	1,982
Accounts receivable, trade, less allowances for doubtful accounts and credit losses $234 (2019, $226)	14,874	14,481
Inventories (Note 2)	8,868	9,020
Prepaid expenses and other	2,358	2,392
Assets held for sale (Note 10)	102	94
Total current assets	44,226	45,274
Property, plant and equipment at cost	43,247	43,332
Less: accumulated depreciation	(25,846)	(25,674)
Property, plant and equipment, net	17,401	17,658
Intangible assets, net (Note 3)	47,338	47,643
Goodwill (Note 3)	33,471	33,639
Deferred taxes on income (Note 5)	7,539	7,819
Other assets	5,042	5,695
Total assets	155,017	157,728
Current liabilities:
Loans and notes payable	2,190	1,202
Accounts payable	7,411	8,544
Accrued liabilities	8,384	9,715
Accrued rebates, returns and promotions	11,608	10,883
Accrued compensation and employee related obligations	2,166	3,354
Accrued taxes on income (Note 5)	1,930	2,266
Total current liabilities	33,689	35,964
Long-term debt (Note 4)	25,393	26,494
Deferred taxes on income (Note 5)	5,766	5,958
Employee related obligations (Note 6)	10,529	10,663
Long-term taxes payable (Note 5)	7,402	7,444
Other liabilities	10,944	11,734
Total liabilities	93,723	98,257
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(16,243)	(15,891)
Retained earnings	112,901	110,659
Less: common stock held in treasury, at cost (487,451,000 and 487,336,000 shares)	38,484	38,417
Total shareholders’ equity	61,294	59,471
Total liabilities and shareholders' equity	$ 155,017	$ 157,728

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Mar. 29, 2020	Dec. 29, 2019
Current assets:
Allowances for doubtful accounts	$ 234	$ 226
Shareholders' equity:
Common stock, par value per share	$ 1	$ 1
Common stock, shares authorized	4,320,000,000	4,320,000,000
Common stock, shares issued	3,119,843,000	3,119,843,000
Treasury stock, shares	487,451,000	487,336,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Income Statement [Abstract]
Sales to customers	$ 20,691	$ 20,021
Sales to customers percent to sales	100.00%	100.00%
Cost of products sold	$ 7,062	$ 6,615
Cost of products sold percent to sales	34.10%	33.00%
Gross profit	$ 13,629	$ 13,406
Gross profit percent to sales	65.90%	67.00%
Selling, marketing and administrative expenses	$ 5,203	$ 5,219
Selling marketing and administrative expenses percent to sales	25.10%	26.10%
Research and development expense	$ 2,580	$ 2,858
Research and development expense percent to sales	12.50%	14.30%
In-process research and development	$ 0	$ 890
In-process research and development percent to sales	0.00%	4.40%
Interest income	$ (67)	$ (99)
Interest income percent to sales	(0.30%)	(0.50%)
Interest expense, net of portion capitalized	$ 25	$ 102
Interest expense, net of portion capitalized percent to sales	0.10%	0.50%
Other (income) expense, net	$ (679)	$ (22)
Other (income) expense, net percent to sales	(3.30%)	(0.10%)
Restructuring (Note 12)	$ 58	$ 36
Restructuring charge percent to sales	0.30%	0.20%
Earnings before provision for taxes on income	$ 6,509	$ 4,422
Earnings before provision for taxes on income percent to sales	31.50%	22.10%
Provision for taxes on income	$ 713	$ 673
Provision for taxes on income (Note 5)	3.50%	3.40%
NET EARNINGS	$ 5,796	$ 3,749
Net earnings percent to sales	28.00%	18.70%
NET EARNINGS PER SHARE
Basic (per share)	$ 2.20	$ 1.41
Diluted (per share)	$ 2.17	$ 1.39
AVG. SHARES OUTSTANDING
Basic (shares)	2,633.7	2,660.8
Diluted (shares)	2,671	2,698.8

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net earnings	$ 5,796	$ 3,749
Other comprehensive income (loss), net of tax
Foreign currency translation	(1,519)	(258)
Securities:
Unrealized holding gain (loss) arising during period	2	0
Reclassifications to earnings	0	0
Net change	2	0
Employee benefit plans:
Prior service cost amortization during period	(6)	(7)
Gain (loss) amortization during period	201	176
Net change	195	169
Derivatives & hedges:
Unrealized gain (loss) arising during period	832	(302)
Reclassifications to earnings	138	96
Net change	970	(206)
Other comprehensive income (loss)	(352)	(295)
Comprehensive income	5,444	3,454
Foreign Currency Translation	(46)	(61)
Securities	(1)	0
Employee Benefit Plans	56	1
Derivatives & Hedges	$ (256)	$ (55)

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Retained Earnings	Accumulated Other Comprehensive Income	Common Stock Issued Amount	Treasury Stock Amount
Beginning Balance at Dec. 30, 2018	$ 59,752	$ 106,216	$ (15,222)	$ 3,120	$ (34,362)
Net earnings	3,749	3,749
Cash dividends paid	(2,396)	(2,396)
Employee compensation and stock option plans	351	(919)			1,270
Repurchase of common stock	(2,206)				(2,206)
Other	0
Other comprehensive income (loss), net of tax	(295)		(295)
Ending Balance at Mar. 31, 2019	58,955	106,650	(15,517)	3,120	(35,298)
Beginning Balance at Dec. 29, 2019	59,471	110,659	(15,891)	3,120	(38,417)
Net earnings	5,796	5,796
Cash dividends paid	(2,505)	(2,505)
Employee compensation and stock option plans	595	(1,049)			1,644
Repurchase of common stock	(1,711)				(1,711)
Other comprehensive income (loss), net of tax	(352)		(352)
Ending Balance at Mar. 29, 2020	$ 61,294	$ 112,901	$ (16,243)	$ 3,120	$ (38,484)

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 0.95	$ 0.90

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 5,796	$ 3,749
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	1,747	1,761
Stock based compensation	263	258
Asset write-downs	11	913
Contingent consideration reversal	(983)	0
Net gain on sale of assets/businesses	0	(72)
Deferred tax provision	54	(362)
Accounts receivable allowances and credit losses	22	(3)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
(Increase) / Decrease in accounts receivable	(812)	157
Increase in inventories	(159)	(369)
Decrease in accounts payable and accrued liabilities	(2,523)	(1,833)
Decrease / (Increase) in other current and non-current assets	271	(488)
Decrease in other current and non-current liabilities	(329)	(168)
NET CASH FLOWS FROM OPERATING ACTIVITIES	3,358	3,543
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(625)	(656)
Proceeds from the disposal of assets/businesses, net	17	253
Acquisitions, net of cash acquired	(939)	(1,683)
Purchases of investments	(2,064)	(730)
Sales of investments	1,544	1,495
Proceeds from credit support agreements, net	1,743	0
Other	(257)	(96)
NET CASH USED BY INVESTING ACTIVITIES	(581)	(1,417)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(2,505)	(2,396)
Repurchase of common stock	(1,711)	(2,206)
Proceeds from short-term debt	10	13
Repayment of short-term debt	(18)	(16)
Repayment of long-term debt	(11)	(1,002)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	332	94
Other	(412)	(3)
NET CASH USED BY FINANCING ACTIVITIES	(4,315)	(5,516)
Effect of exchange rate changes on cash and cash equivalents	(237)	17
Decrease in cash and cash equivalents	(1,775)	(3,373)
Cash and Cash equivalents, beginning of period	17,305	18,107
Cash and Cash equivalents, end of period	15,530	14,734
Acquisitions
Fair value of assets acquired	1,136	2,154
Fair value of liabilities assumed and noncontrolling interests	(197)	(471)
Net cash paid for acquisitions	939	$ 1,683
Auris Health
Adjustments to reconcile net earnings to cash flows from operating activities:
Contingent consideration reversal	$ (983)

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 29, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019 . The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. Use of Estimates The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of March 29, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended March 29, 2020, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. New Accounting Standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements and below describes the impacts from newly adopted standards, as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019. Recently Adopted Accounting Standards ASU 2018-18: Collaborative Arrangements The Company adopted this standard as of the beginning of the fiscal year 2020. This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. ASU 2016-13: Financial Instruments - Credit Losses The Company adopted this standard as of the beginning of the fiscal year 2020. This update introduces the current expected credit loss (CECL) model, which requires an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Inventories

Inventories	3 Months Ended
	Mar. 29, 2020
Inventory Disclosure [Abstract]
Inventories	INVENTORIES (Dollars in Millions) March 29, 2020 December 29, 2019 Raw materials and supplies $ 1,213 1,117 Goods in process 2,252 1,832 Finished goods 5,403 6,071 Total inventories (1) $ 8,868 9,020 (1) See Note 10 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Mar. 29, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2019 . Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) March 29, 2020 December 29, 2019 Intangible assets with definite lives: Patents and trademarks — gross $ 36,214 36,634 Less accumulated amortization 13,857 13,154 Patents and trademarks — net 22,357 23,480 Customer relationships and other intangibles — gross 22,084 22,056 Less accumulated amortization 9,728 9,462 Customer relationships and other intangibles — net* 12,356 12,594 Intangible assets with indefinite lives: Trademarks 6,829 6,922 Purchased in-process research and development (1) 5,796 4,647 Total intangible assets with indefinite lives 12,625 11,569 Total intangible assets — net $ 47,338 47,643 *The majority is comprised of customer relationships (1) In the fiscal first quarter of 2020, the Company completed the acquisition of bermekimab and certain related assets from XBiotech Inc. as well as the acquisition of all outstanding shares in Verb Surgical Inc. and recorded in-process research and development intangible assets of $0.8 billion and $0.4 billion , respectively. Goodwill as of March 29, 2020 was allocated by segment of business as follows: (Dollars in Millions) Consumer Health Pharmaceutical Medical Devices Total Goodwill at December 29, 2019 $ 9,736 9,169 14,734 33,639 Goodwill, related to acquisitions — 1 156 157 Currency translation/Other (223 ) (96 ) (6 ) (325 ) Goodwill at March 29, 2020 $ 9,513 9,074 14,884 33,471 The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion for each of the fiscal first quarters ended March 29, 2020 and March 31, 2019 . Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2020 2021 2022 2023 2024 $4,500 4,300 4,100 4,100 4,000 See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 29, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of March 29, 2020 , the total amount of cash collateral held by the Company under the credit support agreements (CSA) amounted to $2.0 billion , net. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of March 29, 2020 , the Company had notional amounts outstanding for forward foreign exchange contracts, and cross currency interest rate swaps of $44.0 billion , and $20.1 billion respectively. As of December 29, 2019 , the Company had notional amounts outstanding for forward foreign exchange contracts, and cross currency interest rate swaps of $45.3 billion and $20.1 billion respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of March 29, 2020 , the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $675 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months , excluding interest rate contracts, net investment hedges and equity collar contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2020 and 2019 , net of tax: March 29, 2020 March 31, 2019 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 40 — — — — 38 — Amount of gain or (loss) recognized in AOCI — — — 40 — — — — 38 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 9 (173 ) (110 ) — (2 ) (21 ) (35 ) (139 ) — 6 Amount of gain or (loss) recognized in AOCI 11 302 (110 ) — (36 ) (6 ) (296 ) (110 ) — (13 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 98 — — — 55 — Amount of gain or (loss) recognized in AOCI $ — — — 625 — — — — 59 — The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters 2020 and 2019: Gain/(Loss) Recognized In Income on Derivative (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal First Quarter Ended Derivatives Not Designated as Hedging Instruments March 29, 2020 March 31, 2019 Foreign Exchange Contracts Other (income) expense $ 89 (38 ) The following table is the effect of net investment hedges for the fiscal first quarters ended in 2020 and 2019 Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) March 29, 2020 March 31, 2019 March 29, 2020 March 31, 2019 Debt $ 46 71 Interest (income) expense — — Cross Currency interest rate swaps $ 827 370 Interest (income) expense — — The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments: (Dollars in Millions) December 29, 2019 March 29, 2020 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,148 (327 ) 5 826 826 Equity Investments without readily determinable value $ 712 (33 ) 15 694 694 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For equity investments without readily determinable market values, $33 million of the decrease in the fair value reflected in net income were the result of impairments. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of March 29, 2020 and December 29, 2019 were as follows: March 29, 2020 December 29, 2019 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 941 — 941 209 Interest rate contracts (2)(3) — 1,569 — 1,569 693 Total — 2,510 — 2,510 902 Liabilities: Forward foreign exchange contracts — 530 — 530 426 Interest rate contracts (3) — 247 — 247 193 Total — 777 — 777 619 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 120 — 120 23 Liabilities: Forward foreign exchange contracts — 106 — 106 33 Other Investments: Equity investments (4) 826 — — 826 1,148 Debt securities (5) $ — 5,673 — 5,673 4,368 Other Liabilities Contingent consideration (6) 784 784 1,715 Gross to Net Derivative Reconciliation March 29, 2020 December 29, 2019 (Dollars in Millions) Total Gross Assets $ 2,630 925 Credit Support Agreement (CSA) (2,530 ) (841 ) Total Net Asset 100 84 Total Gross Liabilities 883 652 Credit Support Agreement (CSA) (531 ) (586 ) Total Net Liabilities $ 352 66 Summarized information about changes in liabilities for contingent consideration is as follows: Fiscal first quarter ended March 29, 2020 March 31, 2019 (Dollars in Millions) Beginning Balance $ 1,715 $ 397 Changes in estimated fair value (7) (977 ) 32 Additions 106 23 Payments (60 ) — Ending Balance $ 784 $ 452 (1) December 30, 2019 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,148 million , which are classified as Level 1 and contingent consideration of $1,715 million, classified as Level 3. (2) Includes $1 million of non-current other assets as of March 29, 2020 and December 29, 2019 . (3) Includes cross currency interest rate swaps and interest rate swaps. (4) Classified as non-current other assets. (5) Classified within cash equivalents and current marketable securities. (6) Includes $759 million and $1,631 million (primarily related to Auris Health), classified as non-current other liabilities as of March 29, 2020 and December 29, 2019 , respectively. Includes $25 million and $84 million classified as current liabilities as of March 29, 2020 and December 29, 2019 , respectively. (7) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. During the fiscal first quarter of 2020, the Company recorded a contingent consideration reversal of $983 million related to the timing of certain developmental milestones associated with the Auris Health acquisition. The one-time reversal of the contingent consideration was recorded in Other income and expense. As of March 29, 2020 the estimated fair value of the remaining contingent consideration is $165 million . For additional details see Note 10 t o the Consolidated Financial Statements. The Company's cash, cash equivalents and current marketable securities as of March 29, 2020 comprised: (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,499 — — 2,499 2,499 Non-U.S. sovereign securities (1) 90 — — 90 90 — U.S. reverse repurchase agreements 3,965 — — 3,965 3,965 — Other reverse repurchase agreements 473 — — 473 473 Corporate debt securities (1) 2,135 1 (1 ) 2,135 1,039 1,096 Money market funds 2,424 — — 2,424 2,424 Time deposits (1) 765 — — 765 765 Subtotal 12,351 1 (1 ) 12,351 11,255 1,096 Unrealized Gain Unrealized Loss U.S. Gov't securities 5,418 4 — 5,422 4,260 1,162 Corporate debt securities 253 — (2 ) 251 15 236 Subtotal available for sale debt (2) $ 5,671 4 (2 ) 5,673 4,275 1,398 Total cash, cash equivalents and current marketable securities $ 18,022 5 (3 ) 18,024 15,530 2,494 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. In the fiscal year ended December 29, 2019 the carrying amount was the same as the estimated fair value. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities. The contractual maturities of the available for sale securities as of March 29, 2020 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 5,632 5,635 Due after one year through five years 39 38 Due after five years through ten years — — Total debt securities $ 5,671 5,673 Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of March 29, 2020 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 2,190 2,234 Non-Current Debt 3.55% Notes due 2021 449 463 2.45% Notes due 2021 350 356 0.250% Notes due 2022 (1B Euro 1.0980) 1,097 1,096 2.25% Notes due 2022 998 1,019 6.73% Debentures due 2023 250 301 3.375% Notes due 2023 804 875 2.05% Notes due 2023 499 512 0.650% Notes due 2024 (750MM Euro 1.0980) 821 826 5.50% Notes due 2024 (500 MM GBP 1.2023) 597 697 2.625% Notes due 2025 748 796 2.45% Notes due 2026 1,993 2,112 2.95% Notes due 2027 997 1,074 2.90% Notes due 2028 1,494 1,640 1.150% Notes due 2028 (750MM Euro 1.0980) 817 833 6.95% Notes due 2029 297 419 4.95% Debentures due 2033 498 661 4.375% Notes due 2033 856 1,099 1.650% Notes due 2035 (1.5B Euro 1.0980) 1,631 1,699 3.55% Notes due 2036 989 1,172 5.95% Notes due 2037 992 1,477 3.625% Notes due 2037 1,487 1,719 3.40% Notes due 2038 991 1,144 5.85% Debentures due 2038 696 1,072 4.50% Debentures due 2040 539 689 4.85% Notes due 2041 297 432 4.50% Notes due 2043 495 696 3.70% Notes due 2046 1,973 2,406 3.75% Notes due 2047 991 1,230 3.50% Notes due 2048 742 890 Other 5 5 Total Non-Current Debt $ 25,393 29,410 The weighted average effective interest rate on non-current debt is 3.26% . The excess of the estimated fair value over the carrying value of debt was $3.0 billion at December 29, 2019. Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 29, 2020
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The worldwide effective income tax rates for the fiscal first quarters of 2020 and 2019 were 11.0% an d 15.2% , respectively. In the third fiscal quarter of 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF), which became effective on January 1, 2020. More information on the provisions of TRAF can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019 . During the first fiscal quarter of 2020, the final canton where the Company maintains significant operations enacted TRAF legislation and, accordingly, the Company recorded an estimated deferred tax benefit of approximately $0.3 billion for the remeasurement of existing deferred tax liabilities offset by a related $0.2 billion increase in U.S. GILTI deferred taxes (or 1.3% net impact on the Q1 2020 effective tax rate). The Company is currently assessing and awaiting the approval for certain elective transition provisions in several cantons which include discussions with federal and cantonal tax authorities on the application of the new law. The Company has recorded the estimated impact of the transitional provisions based on the best available information for cantons where enactment has occurred, but the Company has not yet received final tax rulings in all cantons. Further, authoritative guidance from the relevant Swiss tax authorities may be issued in the future and additional revisions may be required in the fiscal period they are issued. In the first fiscal quarter of 2020, the Company reduced a contingent consideration liability related to the 2019 Auris Health acquisition that benefited the overall effective tax rate by 1.9% (see Note 10 to the Consolidated Financial Statements for more details). Additionally, the Company had more income in higher tax jurisdictions relative to lower tax jurisdictions as compared to the same period in the prior fiscal year, driven primarily by the one-time charges in the first fiscal quarter of 2019 related to the impairment of the Alios in-process research and development intangible asset taxed in the U.S. at 21.0% and additional tax benefits received from stock based compensation that were either exercised or vested during the fiscal first quarter. As of March 29, 2020 , the Company had approximately $3.2 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2009 and is currently auditing the tax years 2010 through 2012. The Company currently expects completion of this audit and settlement of the related tax liabilities in the fiscal year 2020. As of March 29, 2020, the Company has classified unrecognized tax benefits and related interest of approximately $0.2 billion as a current liability on the “Accrued taxes on Income” line of the Consolidated Balance Sheet. This is the amount expected to be paid over the next 12 months with respect to the IRS audit. During the first fiscal quarter of 2020, the Company made a payment of approximately $0.6 billion to the U.S. Treasury with respect to the 2010-2012 tax audit in anticipation of a final settlement later in the fiscal year 2020. The completion of this tax audit may result in additional adjustments to the Company’s unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	3 Months Ended
	Mar. 29, 2020
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	PENSIONS AND OTHER BENEFIT PLANS Components of Net Periodic Benefit Cost Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for the fiscal first quarters of 2020 and 2019 include the following components: Retirement Plans Other Benefit Plans (Dollars in Millions) March 29, 2020 March 31, 2019 March 29, 2020 March 31, 2019 Service cost $ 326 276 72 68 Interest cost 240 275 33 46 Expected return on plan assets (614 ) (583 ) (2 ) (2 ) Amortization of prior service cost/(credit) — 1 (8 ) (8 ) Recognized actuarial losses 223 144 36 32 Curtailments and settlements 19 (1 ) — — Net periodic benefit cost $ 194 112 131 136 The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings. Company Contributions For the fiscal first quarter ended March 29, 2020 , the Company contributed $23 million and $9 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 29, 2020
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) December 29, 2019 $ (8,705 ) — (6,891 ) (295 ) (15,891 ) Net change (1,519 ) 2 195 970 (352 ) March 29, 2020 $ (10,224 ) 2 (6,696 ) 675 (16,243 ) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 29, 2020
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal first quarters ended March 29, 2020 and March 31, 2019 : Fiscal First Quarter Ended (Shares in Millions) March 29, 2020 March 31, 2019 Basic net earnings per share $ 2.20 1.41 Average shares outstanding — basic 2,633.7 2,660.8 Potential shares exercisable under stock option plans 126.0 136.7 Less: shares which could be repurchased under treasury stock method (89.4 ) (99.4 ) Convertible debt shares 0.7 0.7 Average shares outstanding — diluted 2,671.0 2,698.8 Diluted net earnings per share $ 2.17 1.39 The diluted net earnings per share calculation for both the fiscal first quarters ended March 29, 2020 and March 31, 2019 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for the fiscal first quarter ended March 29, 2020 excluded 10 million shares related to stock options, as the exercise price of these options was greater than their average market value. The diluted net earnings per share calculation for the fiscal first quarter ended March 31, 2019 included all shares related to stock options, as there were no options or other instruments which were anti-dilutive.

Segments of Business and Geogra

Segments of Business and Geographic Areas	3 Months Ended
	Mar. 29, 2020
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS Fiscal First Quarter Ended (Dollars in Millions) March 29, March 31, Percent Change Consumer Health* Baby Care U.S. $ 92 87 6.7 % International 269 307 (12.4 ) Worldwide 361 394 (8.2 ) Skin Health/Beauty U.S. 659 588 12.1 International 458 502 (8.8 ) Worldwide 1,117 1,090 2.5 Oral Care U.S. 176 151 16.2 International 219 216 1.5 Worldwide 395 367 7.6 OTC U.S. 689 507 35.9 International 659 580 13.7 Worldwide 1,348 1,087 24.1 Women's Health U.S. 4 3 32.0 International 228 222 2.5 Worldwide 232 225 2.9 Wound Care/Other U.S. 119 102 17.0 International 52 53 (1.2 ) Worldwide 171 155 10.7 TOTAL Consumer Health U.S. 1,740 1,438 21.0 International 1,885 1,880 0.3 Worldwide 3,625 3,318 9.2 * Previously referred to as Consumer PHARMACEUTICAL Immunology U.S. 2,410 2,163 11.4 International 1,228 1,088 12.8 Worldwide 3,638 3,251 11.9 REMICADE ® U.S. 625 774 (19.3 ) U.S. Exports 110 76 44.3 International 256 252 1.5 Worldwide 990 1,102 (10.2 ) SIMPONI / SIMPONI ARIA ® U.S. 272 263 3.4 International 258 261 (1.2 ) Worldwide 529 524 1.1 STELARA ® U.S. 1,217 882 37.9 International 603 523 15.2 Worldwide 1,819 1,405 29.5 TREMFYA ® U.S. 187 168 11.5 International 109 49 * Worldwide 296 217 36.4 OTHER IMMUNOLOGY U.S. — — — International 3 3 (6.9) Worldwide 3 3 (6.9) Infectious Diseases U.S. 436 357 22.3 International 483 489 (1.2 ) Worldwide 920 846 8.7 EDURANT ® / rilpivirine U.S. 12 12 0.6 International 212 199 6.4 Worldwide 224 211 6.1 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 396 315 25.5 International 184 208 (11.6 ) Worldwide 579 523 10.8 OTHER INFECTIOUS DISEASES U.S. 29 30 (3.4 ) International 87 82 6.7 Worldwide 116 112 4.0 Neuroscience U.S. 748 723 3.3 International 910 905 0.5 Worldwide 1,658 1,629 1.8 CONCERTA ® / methylphenidate U.S. 52 97 (46.1 ) International 118 116 1.5 Worldwide 171 214 (20.1 ) INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 544 483 12.6 International 339 307 10.3 Worldwide 883 790 11.7 RISPERDAL CONSTA ® U.S. 76 77 (0.3 ) International 94 102 (8.7 ) Worldwide 170 179 (5.1 ) OTHER NEUROSCIENCE U.S. 75 66 12.5 International 360 379 (5.1 ) Worldwide 435 446 (2.5 ) Oncology U.S. 1,175 962 22.1 International 1,839 1,556 18.2 Worldwide 3,013 2,518 19.7 DARZALEX ® U.S. 463 352 31.8 International 474 277 70.9 Worldwide 937 629 49.0 ERLEADA ® U.S. 119 58 * International 24 3 * Worldwide 143 61 * IMBRUVICA ® U.S. 432 349 23.9 International 599 435 37.8 Worldwide 1,031 784 31.6 VELCADE ® U.S. — — — International 108 263 (59.0 ) Worldwide 108 263 (59.0 ) ZYTIGA ® / abiraterone acetate U.S. 139 185 (25.2 ) International 552 494 11.7 Worldwide 690 679 1.6 OTHER ONCOLOGY U.S. 22 18 20.1 International 82 84 (2.7) Worldwide 104 102 1.3 Pulmonary Hypertension U.S. 486 430 13.0 International 260 226 14.9 Worldwide 745 656 13.7 OPSUMIT ® U.S. 229 172 33.0 International 160 133 20.2 Worldwide 389 306 27.4 UPTRAVI ® U.S. 212 176 20.7 International 38 22 70.2 Worldwide 250 198 26.2 OTHER PULMONARY HYPERTENSION U.S. 44 82 (45.9) International 62 71 (12.4) Worldwide 106 152 (30.4) Cardiovascular / Metabolism / Other U.S. 806 947 (14.9 ) International 354 398 (11.0 ) Worldwide 1,160 1,345 (13.8 ) XARELTO ® U.S. 527 542 (2.7 ) International — — — Worldwide 527 542 (2.7 ) INVOKANA ® / INVOKAMET ® U.S. 117 154 (23.6 ) International 58 49 18.6 Worldwide 175 202 (13.5 ) PROCRIT ® / EPREX ® U.S. 76 148 (48.5 ) International 79 78 0.4 Worldwide 155 226 (31.6 ) OTHER U.S. 85 104 (18.0 ) International 217 271 (19.7 ) Worldwide 302 374 (19.2 ) TOTAL PHARMACEUTICAL U.S. 6,061 5,582 8.6 International 5,073 4,662 8.8 Worldwide 11,134 10,244 8.7 MEDICAL DEVICES Interventional Solutions U.S. 365 343 6.6 International 362 389 (6.9 ) Worldwide 727 732 (0.6 ) Orthopaedics U.S. 1,250 1,318 (5.2 ) International 788 885 (11.0 ) Worldwide 2,038 2,204 (7.5 ) HIPS U.S. 206 213 (3.6 ) International 132 148 (11.2 ) Worldwide 337 361 (6.7 ) KNEES U.S. 214 223 (4.2 ) International 130 146 (11.4 ) Worldwide 343 369 (7.0 ) TRAUMA U.S. 407 417 (2.3 ) International 247 268 (8.0 ) Worldwide 654 685 (4.5 ) SPINE, SPORTS & OTHER U.S. 423 465 (8.9 ) International 280 323 (13.3 ) Worldwide 703 788 (10.7 ) Surgery U.S. 844 1,001 (15.7 ) International 1,257 1,394 (9.8 ) Worldwide 2,100 2,395 (12.3 ) ADVANCED U.S. 381 404 (5.7 ) International 567 576 (1.6 ) Worldwide 948 980 (3.3 ) GENERAL U.S. 463 597 (22.5 ) International 690 818 (15.7 ) Worldwide 1,153 1,414 (18.5 ) Vision U.S. 439 446 (1.6 ) International 628 682 (8.0 ) Worldwide 1,067 1,129 (5.5 ) CONTACT LENSES / OTHER U.S. 346 321 7.7 International 467 502 (7.0 ) Worldwide 814 824 (1.3 ) SURGICAL U.S. 93 125 (25.5 ) International 160 180 (11.0 ) Worldwide 253 305 (16.9 ) TOTAL MEDICAL DEVICES U.S. 2,898 3,109 (6.8 ) International 3,034 3,350 (9.4 ) Worldwide 5,932 6,459 (8.2 ) WORLDWIDE U.S. 10,699 10,129 5.6 International 9,992 9,892 1.0 Worldwide $ 20,691 20,021 3.3 % *Percentage greater than 100% or not meaningful EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT Fiscal First Quarter Ended (Dollars in Millions) March 29, March 31, Percent Change Consumer Health (1) $ 770 741 3.9 % Pharmaceutical (2) 3,834 2,331 64.5 Medical Devices (3) 2,025 1,497 35.3 Segment earnings before provision for taxes 6,629 4,569 45.1 Less: Expense not allocated to segments (4) 120 147 Worldwide income before tax $ 6,509 4,422 47.2 % (1) Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (DR. CI: LABO) in the fiscal first quarter of 2019. Includes amortization expense of $0.1 billion in both the fiscal first quarters of 2020 and 2019, respectively. (2) Includes an in-process research and development expense of $0.9 billion related to the Alios asset in the fiscal first quarter of 2019. Includes litigation expense of $0.1 billion and $0.3 billion in the fiscal first quarter of 2020 and 2019, respectively. Includes an unrealized loss on securities of $0.3 billion in the fiscal first quarter of 2020 and an unrealized gain on securities of $0.1 billion in the fiscal first quarter of 2019. Additionally, the fiscal first quarter of 2019 includes a research and development expense of $0.3 billion for an upfront payment related to argenx. Includes amortization expense of $0.8 billion in both the fiscal first quarters of 2020 and 2019. (3) Includes a contingent consideration reversal of $1.0 billion in the fiscal first quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. Includes litigation expense of $0.1 billion in the fiscal first quarter of 2019. Includes a restructuring related charge of $0.1 billion and amortization expense of $0.2 billion in both the fiscal first quarters of 2020 and 2019. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA Fiscal First Quarter Ended (Dollars in Millions) March 29, 2020 March 31, 2019 Percent Change United States $ 10,699 10,129 5.6 % Europe 4,827 4,609 4.7 Western Hemisphere, excluding U.S. 1,502 1,503 (0.1 ) Asia-Pacific, Africa 3,663 3,780 (3.1 ) Total $ 20,691 20,021 3.3 %

Business Combinations and Dives

Business Combinations and Divestitures	3 Months Ended
	Mar. 29, 2020
Business Combinations [Abstract]
Business Combinations and Divestitures	BUSINESS COMBINATIONS AND DIVESTITURES During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion . The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.8 billion . XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. Additionally, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with world-class robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.4 billion , goodwill for $0.2 billion , other assets of $0.2 billion and liabilities assumed of $0.3 billion . The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4 billion . On April 1, 2019, the Company completed the acquisition of Auris Health, Inc. for approximately $3.4 billion , net of cash acquired. Additional contingent payments of up to $2.35 billion , in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&D, for $3.0 billion , goodwill for $2.0 billion , marketable securities of $0.2 billion and liabilities assumed of $1.8 billion , which includes the fair value of the contingent payments mentioned above, subject to any subsequent valuation adjustments within the measurement period. As of March 29, 2020, there were no valuation adjustments to the assets acquired but during the fiscal first quarter of 2020, the Company recorded Other income of $1.0 billion for the reversal of the contingent consideration related to the timing of certain developmental and commercial milestones, which are not expected to be met based on the Company’s current timelines. As of March 29, 2020, the fair value of the remaining contingent consideration is $0.2 billion . Further, the Company re-assessed the current value of the Auris IPR&D assets in connection with the modified development timeline and determined the fair value still exceeds the carrying value. On January 17, 2019, the Company acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately ¥230 billion , which equates to approximately $2.1 billion , using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO. The Company treated this transaction as a business combination and included it in the Consumer Health segment. During the fiscal first quarter of 2020, the Company finalized the purchase price allocation. At March 29, 2020, the fair value of the acquisition was allocated primarily to amortizable intangible assets for $1.5 billion , goodwill for $1.2 billion and liabilities assumed of $0.4 billion . The adjustments made since the date of acquisition were $0.1 billion to intangible assets, accrued liabilities, deferred taxes on income and property, plant and equipment with the offset to goodwill. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of 15.3 years . The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. During the fiscal third quarter of 2018, the Company accepted a binding offer to form a strategic collaboration with Jabil Inc., one of the world’s leading manufacturing services providers for health care products and technology products. The Company is expanding a 12-year relationship with Jabil Inc. to produce a range of products within the Ethicon Endo-Surgery and DePuy Synthes businesses. This transaction includes the transfer of certain employees and manufacturing sites. The majority of the transfers were completed in 2019 with a minor amount remaining in 2020. As of March 29, 2020, the assets held for sale on the Consolidated Balance Sheet were $0.1 billion of inventory and property, plant and equipment, net. For additional details on the global supply chain restructuring see Note 12 to the Consolidated Financial Statements.

Legal Proceedings

Legal Proceedings	3 Months Ended
	Mar. 29, 2020
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	LEGAL PROCEEDINGS Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation develops. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of March 29, 2020 , the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; the PINNACLE ® Acetabular Cup System; pelvic meshes; RISPERDAL ® ; XARELTO ® ; body powders containing talc, primarily JOHNSONS ® Baby Powder; INVOKANA ® ; and ETHICON PHYSIOMESH ® Flexible Composite Mesh. As of March 29, 2020 , in the United States there were approximately 940 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; 9,500 with respect to the PINNACLE ® Acetabular Cup System; 16,500 with respect to pelvic meshes; 10,900 with respect to RISPERDAL ® ; 24,600 with respect to XARELTO ® ; 19,400 with respect to body powders containing talc; 300 with respect to INVOKANA ® ; and 3,500 with respect to ETHICON PHYSIOMESH ® Flexible Composite Mesh. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR ™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle two pending class actions which have been approved by the Québec Superior Court and the Supreme Court of British Columbia. The British Columbia order is currently the subject of the Company's appeal to broaden the scope of participants. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR ™ Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson & Johnson (collectively, DePuy) relating to the PINNACLE ® Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE ® Acetabular Cup System and the related settlement program. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. The MDL Court is remanding cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and Belgium, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court entered damages awards to the three Lead Applicants. With respect to other group members, there will be an individual case assessment process which will require proof of use and causally related loss. The class actions in Canada are expected to be discontinued in 2020 as a result of a settlement of a group of cases, subject to court approval of the discontinuance. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products. Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH ® Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. and Johnson & Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) has also been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending outside the United States. Along with ETHICON PHYSIOMESH ® lawsuits, there were a number of filings related to the PROCEED ® Mesh and PROCEED ® Ventral Patch products. In March 2019, the New Jersey Supreme Court entered an order consolidating all PROCEED ® and PROCEED ® Ventral Patch cases as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. The Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH ® Flexible Composite Mesh, PROCEED ® Mesh and PROCEED ® Ventral Patch products. In September 2019, plaintiffs’ attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PROLENE™ Polypropylene Hernia System cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those will be transferred to an MCL in Atlantic County Superior Court. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a recent verdict in October 2019 of $8 billion of punitive damages related to one single plaintiff which was subsequently reduced in January 2020 to $6.8 million by the trial judge. The Company will appeal the final judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals. Claims for personal injury arising out of the use of XARELTO ® , an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson & Johnson (J&J); and JPI’s collaboration partner for XARELTO ® , Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases have been consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and J&J announced an agreement in principle to the settle the XARELTO ® cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO ® related product liability litigation. Personal injury claims alleging that talc causes cancer have been made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of body powders containing talc, primarily JOHNSON’S ® Baby Powder. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California, as well as outside the United States. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. In the multi-district litigation, the parties have moved to exclude experts, known as Daubert motions. The Court held Daubert hearings in mid-July 2019 and a final round of briefing was submitted to the Court. In April 2020, the Court issued rulings which limit the scope of testimony, including some theories and testing methods, for certain plaintiff expert witnesses and denied the attempt to limit the scope of testimony of certain of the Company’s witnesses. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in July 2018 of $4.7 billion . The Company believes that it has strong grounds on appeal to overturn these verdicts. The Company has established an accrual primarily for defense costs in connection with product liability litigation associated with body powders containing talc. In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’ potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it alleges it has against the Company for indemnification and rights to joint insurance proceeds. Based on such claims as well as indemnity and insurance claims the Company has against Imerys, the Company petitioned the United States District Court for the District of Delaware to establish federal jurisdiction of the state court talc lawsuits under the Bankruptcy Code. The Company's petition was denied and the state court talc lawsuits that have been removed to federal court on such basis have been remanded. The Company previously proposed to resolve Imerys' (and the Company’s) obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, waiving the Company’s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. In addition, the Company has objected to Imerys’ fourth request to extend the time during which the debtor has the exclusive right to file a Chapter 11 plan. In February 2018, a securities class action lawsuit was filed against Johnson & Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson & Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S ® Baby Powder, and that purchasers of Johnson & Johnson’s shares suffered losses as a result. Plaintiffs are seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. In October 2018, a shareholder derivative lawsuit was filed against Johnson & Johnson as the nominal defendant and its current directors as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder, and that Johnson & Johnson has suffered damages as a result of those alleged breaches. In June 2019, the shareholder filed an additional complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson & Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In September 2019, the United States District Court for the District of New Jersey granted defendants’ motion to dismiss the shareholder derivative lawsuit, and dismissed the complaint without prejudice. In October 2019, the shareholder filed a notice of appeal with the United States Court of Appeals for the Third Circuit. In January 2020, the shareholder voluntarily dismissed his appeal, with prejudice. Four additional shareholder derivative lawsuits have been filed in New Jersey making similar allegations against the Company and its current directors and certain officers. In February 2020, these four cases were consolidated into a single action under the caption In re Johnson & Johnson Talc Stockholder Derivative Litigation , and the shareholders have until May 2020 to file a consolidated complaint or identify a previously filed complaint as the operative complaint. In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson & Johnson Savings Plan against Johnson & Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson & Johnson stock as a Johnson & Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder. Plaintiffs are seeking damages and injunctive relief. Defendants filed a motion to dismiss. In April 2020, the Court granted the motion to dismiss but granted leave to amend. A lawsuit is pending in the Superior Court of California for the County of San Diego alleging violations of California’s Consumer Legal Remedies Act relating to JOHNSON’S ® Baby Powder. In that lawsuit, the plaintiffs allege that Johnson & Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In January 2020, the Abtahi Law Group filed an action under Proposition 65 against Johnson & Johnson and Johnson & Johnson Consumer Inc. as well as a number of other alleged talcum powder manufacturers and distributors, including one California company. In that action, the plaintiff alleges contamination of talcum powder products with unsafe levels of arsenic, hexavalent chromium and lead. The plaintiff seeks civil penalties and injunctive relief. In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding these matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Securities and Exchange Commission and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company is cooperating with government inquiries and continues to produce documents in response. Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson & Johnson, arising out of the use of INVOKANA ® , a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. Lawsuits filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals. INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. The most significant of these matters are described below. Medical Devices In March 2013, Medinol Ltd. (Medinol) filed a patent infringement lawsuit against Cordis Corporation (Cordis) and Johnson & Johnson in the United States District Court for the Southern District of New York alleging that Cordis’s sales of the CYPHER ™ and CYPHER SELECT ™ stents made in the United States since 2005 willfully infringed four of Medinol's patents directed to the geometry of articulated stents. Although Johnson & Johnson has since sold Cordis, it has retained liability for this case. After the trial in January 2014, the district court dismissed the case, finding Medinol unreasonably delayed bringing its claims (the laches defense). In September 2014, the district court denied a motion by Medinol to vacate the judgment and grant it a new trial. Medinol appealed the decision to the United States Court of Appeals for the Federal Circuit. In March 2017, the United States Supreme Court held that the laches defense is not available in patent cases. In April 2018, the United States Court of Appeals for the Federal Circuit remanded the case back to the district court to reconsider Medinol’s motion for a new trial. In March 2019, the district court denied Medinol’s motion for a new trial. In April 2019, Medinol appealed, and the appellate court will conduct a hearing in June 2020. In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE ® Knee System. In April 2017, MedIdea filed an amended complaint adding DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. as named defendants (collectively, DePuy). MedIdea alleges infringement of United States Patent Nos. 6,558,426 (’426); 8,273,132 (’132); 8,721,730 (’730) and 9,492,280 (’280) relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM TM Contact feature of the ATTUNE ® posterior stabilized knee products infringes the patents-in-suit. MedIdea is seeking monetary damages and injunctive relief. In June 2017, the case was transferred to the United States District Court for the District of Massachusetts. A claim construction hearing was held in October 2018, and a claim construction order was issued in November 2018. In December 2018, MedIdea stipulated to non-infringement of the ’132, ’730 and ’280 patents, based on the district court’s claim construction and reserving its right to appeal that construction, leaving only the ’426 patent at issue before the district court. In January 2019, the district court stayed the case pending a decision in the Inter Partes Review proceeding on the ’426 patent (see below). In December 2017, DePuy Synthes Products, Inc. filed a petition for Inter Partes Review with the United States Patent and Trademark Office (USPTO), seeking to invalidate the two claims of the ’426 patent asserted in the district court litigation, and in June 2018, the USPTO instituted review of those claims. A hearing was held in March 2019, and in April 2019, the USPTO issued its decision upholding the validity of the patent. In May 2019, DePuy filed a motion for summary judgment of non-infringement of the claims of the ’426 patent. In November 2019, judgment was entered in favor of DePuy. In December 2019, MedIdea filed a notice of appeal. In December 2016, Ethicon Endo-Surgery, Inc. and Ethicon Endo-Surgery, LLC (now known as Ethicon LLC) sued Covidien, Inc. in the United States District Court for the District of Massachusetts seeking a declaration that United States Patent Nos. 6,585,735 (the ’735 patent); 7,118,587; 7,473,253; 8,070,748 and 8,241,284 (the ’284 patent), are either invalid or not infringed by Ethicon’s ENSEAL ® X1 Large Jaw Tissue Sealer product. In April 2017, Covidien LP, Covidien Sales LLC, and Covidien AG (collectively, Covidien) answered and counterclaimed, denying the allegations, asserting willful infringement of the ’735 patent, the ’284 patent and United States Patent Nos. 8,323,310 (the ’310 patent); 9,084,608; 9,241,759 (the ’759 patent) and 9,113,882, and seeking damages and an injunction. Covidien filed a motion for preliminary injunction, which was denied in October 2017. The parties have entered joint stipulations such that only the ’310 patent and the ’759 patent remain in dispute. A bench trial concluded in March 2020. In April 2020, the district court issued a decision in Ethicon’s favor, finding that the ENSEAL ® X1 device does not infringe any asserted claim. In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent’s RELIEVA ® Spin and RELIEVEA SpinPlus ® products infringe U.S. Patent No. 9,011,412 (the ’412 patent). Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent’s U.S. Patent No. 8,414,473. In December 2016, Acclarent filed a petition for Inter Partes Review (IPR) with the United States Patent and Trademark Office (USPTO) challenging the validity of the ’412 patent. The USPTO instituted the IPR in July 2017. In July 2018, the USPTO ruled in favor of Albritton in the IPR, finding that Acclarent had not met its burden of proof that the challenged claims were invalid. In October 2019, the Court of Appeals affirmed the USPTO’s Patent Trial and Appeal Board. In June 2019, the parties filed cross motions for summary judgment in the district court. The district court denied most motions for summary judgment, and trial will go forward on all of Dr. Albritton’s claims. The trial is scheduled to begin in September 2020. In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC alleging the manufacture and sale of VICRYL ® Plus Antibacterial Sutures, MONOCRYL ® Plus Antibacterial Sutures, PDS ® Plus Antibacterial Sutures, STRATAFIX ® PDS ® Antibacterial Sutures and STRATAFIX ® MONOCRYL ® Plus Antibacterial Sutures infringe plaintiffs’ United States Patent Nos. 6,596,296 and 7,033,603 (the ’603 patent) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. UT is seeking damages and an injunction. In December 2018, Ethicon filed petitions with the USPTO, seeking Inter Partes Review (IPR) of both asserted patents. Those petitions have been stayed by the USPTO pending a decision by the U.S. Supreme Court in an unrelated case. The stay has been lifted and the USPTO’s institution decision is expected in June 2020. UT dismissed the ’603 patent from the suit and no longer accuses PDS ® Plus Antibacterial Sutures or STRATAFIX ® PDS ® Plus Antibacterial Sutures of infringement. The district court trial is scheduled for June 2020. In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (“Intuitive”) filed a patent infringement suit against Auris Health, Inc. (“Auris”) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (’200 patent); 6,491,701 (’701 patent); 6,522,906 (’906 patent); 6,800,056 (’056 patent); 8,142,447 (’447 patent); 8,620,473 (’473 patent); 8,801,601 (’601 patent); and 9,452,276 (’276 patent) based on Auris’ Monarch™ Platform. Auris filed Petitions for Inter Partes Review with the USPTO regarding the ’200, ’056, ’601 ’701, ’447, ’276 and ’906 patents. Intuitive subsequently dropped the ’200 and ’701 patents from

Restructuring

Restructuring	3 Months Ended
	Mar. 29, 2020
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING The Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. For additional details on the global supply chain restructuring strategic collaborations see Note 10 to the Consolidated Financial Statements. In the fiscal first quarter of 2020, the Company recorded a pre-tax charge of $118 million , which is included on the following lines of the Consolidated Statement of Earnings, $58 million in restructuring, $15 million in cost of products sold and $45 million in other (income) expense. Total project costs of approximately $1.0 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion , over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization. The following table summarizes the severance related reserves and the associated spending through the fiscal first quarter of 2020: (Dollars in Millions) Severance Asset Write-offs Other (2) Total Reserve balance, December 29, 2019 $ 164 — 16 180 Current year activity: Charges — 11 107 118 Cash payments (6 ) — (99 ) (105 ) Settled non cash — (11 ) (17 ) (3) (28 ) Reserve balance, March 29, 2020 (1) $ 158 — 7 165 (1) Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Relates to pension related actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 29, 2020
Accounting Policies [Abstract]
New Accounting Standards Recently Adopted And Not Adopted	New Accounting Standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements and below describes the impacts from newly adopted standards, as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019. Recently Adopted Accounting Standards ASU 2018-18: Collaborative Arrangements The Company adopted this standard as of the beginning of the fiscal year 2020. This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. ASU 2016-13: Financial Instruments - Credit Losses The Company adopted this standard as of the beginning of the fiscal year 2020. This update introduces the current expected credit loss (CECL) model, which requires an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Fair Value Measurements (Polici

Fair Value Measurements (Policies)	3 Months Ended
	Mar. 29, 2020
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents, Policy	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 29, 2020
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) March 29, 2020 December 29, 2019 Raw materials and supplies $ 1,213 1,117 Goods in process 2,252 1,832 Finished goods 5,403 6,071 Total inventories (1) $ 8,868 9,020 (1) See Note 10 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures.

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended
	Mar. 29, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	(Dollars in Millions) March 29, 2020 December 29, 2019 Intangible assets with definite lives: Patents and trademarks — gross $ 36,214 36,634 Less accumulated amortization 13,857 13,154 Patents and trademarks — net 22,357 23,480 Customer relationships and other intangibles — gross 22,084 22,056 Less accumulated amortization 9,728 9,462 Customer relationships and other intangibles — net* 12,356 12,594 Intangible assets with indefinite lives: Trademarks 6,829 6,922 Purchased in-process research and development (1) 5,796 4,647 Total intangible assets with indefinite lives 12,625 11,569 Total intangible assets — net $ 47,338 47,643 *The majority is comprised of customer relationships (1) In the fiscal first quarter of 2020, the Company completed the acquisition of bermekimab and certain related assets from XBiotech Inc. as well as the acquisition of all outstanding shares in Verb Surgical Inc. and recorded in-process research and development intangible assets of $0.8 billion and $0.4 billion , respectively.
Goodwill	Goodwill as of March 29, 2020 was allocated by segment of business as follows: (Dollars in Millions) Consumer Health Pharmaceutical Medical Devices Total Goodwill at December 29, 2019 $ 9,736 9,169 14,734 33,639 Goodwill, related to acquisitions — 1 156 157 Currency translation/Other (223 ) (96 ) (6 ) (325 ) Goodwill at March 29, 2020 $ 9,513 9,074 14,884 33,471
Intangible Asset Amortization Expense	The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2020 2021 2022 2023 2024 $4,500 4,300 4,100 4,100 4,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 29, 2020
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2020 and 2019 , net of tax: March 29, 2020 March 31, 2019 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 40 — — — — 38 — Amount of gain or (loss) recognized in AOCI — — — 40 — — — — 38 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 9 (173 ) (110 ) — (2 ) (21 ) (35 ) (139 ) — 6 Amount of gain or (loss) recognized in AOCI 11 302 (110 ) — (36 ) (6 ) (296 ) (110 ) — (13 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 98 — — — 55 — Amount of gain or (loss) recognized in AOCI $ — — — 625 — — — — 59 — The following table is the effect of net investment hedges for the fiscal first quarters ended in 2020 and 2019 Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) March 29, 2020 March 31, 2019 March 29, 2020 March 31, 2019 Debt $ 46 71 Interest (income) expense — — Cross Currency interest rate swaps $ 827 370 Interest (income) expense — —
Schedule of Derivatives Recorded in Consolidated Balance Sheet
Schedule of Effect of Derivatives not Designated as Hedging Instruments	Gain/(Loss) Recognized In Income on Derivative (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal First Quarter Ended Derivatives Not Designated as Hedging Instruments March 29, 2020 March 31, 2019 Foreign Exchange Contracts Other (income) expense $ 89 (38 )
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments: (Dollars in Millions) December 29, 2019 March 29, 2020 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,148 (327 ) 5 826 826 Equity Investments without readily determinable value $ 712 (33 ) 15 694 694 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of March 29, 2020 and December 29, 2019 were as follows: March 29, 2020 December 29, 2019 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 941 — 941 209 Interest rate contracts (2)(3) — 1,569 — 1,569 693 Total — 2,510 — 2,510 902 Liabilities: Forward foreign exchange contracts — 530 — 530 426 Interest rate contracts (3) — 247 — 247 193 Total — 777 — 777 619 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 120 — 120 23 Liabilities: Forward foreign exchange contracts — 106 — 106 33 Other Investments: Equity investments (4) 826 — — 826 1,148 Debt securities (5) $ — 5,673 — 5,673 4,368 Other Liabilities Contingent consideration (6) 784 784 1,715 Gross to Net Derivative Reconciliation March 29, 2020 December 29, 2019 (Dollars in Millions) Total Gross Assets $ 2,630 925 Credit Support Agreement (CSA) (2,530 ) (841 ) Total Net Asset 100 84 Total Gross Liabilities 883 652 Credit Support Agreement (CSA) (531 ) (586 ) Total Net Liabilities $ 352 66 Summarized information about changes in liabilities for contingent consideration is as follows: Fiscal first quarter ended March 29, 2020 March 31, 2019 (Dollars in Millions) Beginning Balance $ 1,715 $ 397 Changes in estimated fair value (7) (977 ) 32 Additions 106 23 Payments (60 ) — Ending Balance $ 784 $ 452 (1) December 30, 2019 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,148 million , which are classified as Level 1 and contingent consideration of $1,715 million, classified as Level 3. (2) Includes $1 million of non-current other assets as of March 29, 2020 and December 29, 2019 . (3) Includes cross currency interest rate swaps and interest rate swaps. (4) Classified as non-current other assets. (5) Classified within cash equivalents and current marketable securities. (6) Includes $759 million and $1,631 million (primarily related to Auris Health), classified as non-current other liabilities as of March 29, 2020 and December 29, 2019 , respectively. Includes $25 million and $84 million classified as current liabilities as of March 29, 2020 and December 29, 2019 , respectively. (7) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. During the fiscal first quarter of 2020, the Company recorded a contingent consideration reversal of $983 million related to the timing of certain developmental milestones associated with the Auris Health acquisition. The one-time reversal of the contingent consideration was recorded in Other income and expense. As of March 29, 2020 the estimated fair value of the remaining contingent consideration is $165 million . For additional details see Note 10 t o the Consolidated Financial Statements.
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of March 29, 2020 comprised: (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,499 — — 2,499 2,499 Non-U.S. sovereign securities (1) 90 — — 90 90 — U.S. reverse repurchase agreements 3,965 — — 3,965 3,965 — Other reverse repurchase agreements 473 — — 473 473 Corporate debt securities (1) 2,135 1 (1 ) 2,135 1,039 1,096 Money market funds 2,424 — — 2,424 2,424 Time deposits (1) 765 — — 765 765 Subtotal 12,351 1 (1 ) 12,351 11,255 1,096 Unrealized Gain Unrealized Loss U.S. Gov't securities 5,418 4 — 5,422 4,260 1,162 Corporate debt securities 253 — (2 ) 251 15 236 Subtotal available for sale debt (2) $ 5,671 4 (2 ) 5,673 4,275 1,398 Total cash, cash equivalents and current marketable securities $ 18,022 5 (3 ) 18,024 15,530 2,494 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities	The contractual maturities of the available for sale securities as of March 29, 2020 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 5,632 5,635 Due after one year through five years 39 38 Due after five years through ten years — — Total debt securities $ 5,671 5,673
Financial Liabilities not Measured at Fair Value	Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of March 29, 2020 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 2,190 2,234 Non-Current Debt 3.55% Notes due 2021 449 463 2.45% Notes due 2021 350 356 0.250% Notes due 2022 (1B Euro 1.0980) 1,097 1,096 2.25% Notes due 2022 998 1,019 6.73% Debentures due 2023 250 301 3.375% Notes due 2023 804 875 2.05% Notes due 2023 499 512 0.650% Notes due 2024 (750MM Euro 1.0980) 821 826 5.50% Notes due 2024 (500 MM GBP 1.2023) 597 697 2.625% Notes due 2025 748 796 2.45% Notes due 2026 1,993 2,112 2.95% Notes due 2027 997 1,074 2.90% Notes due 2028 1,494 1,640 1.150% Notes due 2028 (750MM Euro 1.0980) 817 833 6.95% Notes due 2029 297 419 4.95% Debentures due 2033 498 661 4.375% Notes due 2033 856 1,099 1.650% Notes due 2035 (1.5B Euro 1.0980) 1,631 1,699 3.55% Notes due 2036 989 1,172 5.95% Notes due 2037 992 1,477 3.625% Notes due 2037 1,487 1,719 3.40% Notes due 2038 991 1,144 5.85% Debentures due 2038 696 1,072 4.50% Debentures due 2040 539 689 4.85% Notes due 2041 297 432 4.50% Notes due 2043 495 696 3.70% Notes due 2046 1,973 2,406 3.75% Notes due 2047 991 1,230 3.50% Notes due 2048 742 890 Other 5 5 Total Non-Current Debt $ 25,393 29,410

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	3 Months Ended
	Mar. 29, 2020
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for the fiscal first quarters of 2020 and 2019 include the following components: Retirement Plans Other Benefit Plans (Dollars in Millions) March 29, 2020 March 31, 2019 March 29, 2020 March 31, 2019 Service cost $ 326 276 72 68 Interest cost 240 275 33 46 Expected return on plan assets (614 ) (583 ) (2 ) (2 ) Amortization of prior service cost/(credit) — 1 (8 ) (8 ) Recognized actuarial losses 223 144 36 32 Curtailments and settlements 19 (1 ) — — Net periodic benefit cost $ 194 112 131 136

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 29, 2020
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) December 29, 2019 $ (8,705 ) — (6,891 ) (295 ) (15,891 ) Net change (1,519 ) 2 195 970 (352 ) March 29, 2020 $ (10,224 ) 2 (6,696 ) 675 (16,243 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 29, 2020
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal first quarters ended March 29, 2020 and March 31, 2019 : Fiscal First Quarter Ended (Shares in Millions) March 29, 2020 March 31, 2019 Basic net earnings per share $ 2.20 1.41 Average shares outstanding — basic 2,633.7 2,660.8 Potential shares exercisable under stock option plans 126.0 136.7 Less: shares which could be repurchased under treasury stock method (89.4 ) (99.4 ) Convertible debt shares 0.7 0.7 Average shares outstanding — diluted 2,671.0 2,698.8 Diluted net earnings per share $ 2.17 1.39

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	3 Months Ended
	Mar. 29, 2020
Segment Reporting [Abstract]
Sales By Segment Of Business	SALES BY SEGMENT OF BUSINESS Fiscal First Quarter Ended (Dollars in Millions) March 29, March 31, Percent Change Consumer Health* Baby Care U.S. $ 92 87 6.7 % International 269 307 (12.4 ) Worldwide 361 394 (8.2 ) Skin Health/Beauty U.S. 659 588 12.1 International 458 502 (8.8 ) Worldwide 1,117 1,090 2.5 Oral Care U.S. 176 151 16.2 International 219 216 1.5 Worldwide 395 367 7.6 OTC U.S. 689 507 35.9 International 659 580 13.7 Worldwide 1,348 1,087 24.1 Women's Health U.S. 4 3 32.0 International 228 222 2.5 Worldwide 232 225 2.9 Wound Care/Other U.S. 119 102 17.0 International 52 53 (1.2 ) Worldwide 171 155 10.7 TOTAL Consumer Health U.S. 1,740 1,438 21.0 International 1,885 1,880 0.3 Worldwide 3,625 3,318 9.2 * Previously referred to as Consumer PHARMACEUTICAL Immunology U.S. 2,410 2,163 11.4 International 1,228 1,088 12.8 Worldwide 3,638 3,251 11.9 REMICADE ® U.S. 625 774 (19.3 ) U.S. Exports 110 76 44.3 International 256 252 1.5 Worldwide 990 1,102 (10.2 ) SIMPONI / SIMPONI ARIA ® U.S. 272 263 3.4 International 258 261 (1.2 ) Worldwide 529 524 1.1 STELARA ® U.S. 1,217 882 37.9 International 603 523 15.2 Worldwide 1,819 1,405 29.5 TREMFYA ® U.S. 187 168 11.5 International 109 49 * Worldwide 296 217 36.4 OTHER IMMUNOLOGY U.S. — — — International 3 3 (6.9) Worldwide 3 3 (6.9) Infectious Diseases U.S. 436 357 22.3 International 483 489 (1.2 ) Worldwide 920 846 8.7 EDURANT ® / rilpivirine U.S. 12 12 0.6 International 212 199 6.4 Worldwide 224 211 6.1 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 396 315 25.5 International 184 208 (11.6 ) Worldwide 579 523 10.8 OTHER INFECTIOUS DISEASES U.S. 29 30 (3.4 ) International 87 82 6.7 Worldwide 116 112 4.0 Neuroscience U.S. 748 723 3.3 International 910 905 0.5 Worldwide 1,658 1,629 1.8 CONCERTA ® / methylphenidate U.S. 52 97 (46.1 ) International 118 116 1.5 Worldwide 171 214 (20.1 ) INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 544 483 12.6 International 339 307 10.3 Worldwide 883 790 11.7 RISPERDAL CONSTA ® U.S. 76 77 (0.3 ) International 94 102 (8.7 ) Worldwide 170 179 (5.1 ) OTHER NEUROSCIENCE U.S. 75 66 12.5 International 360 379 (5.1 ) Worldwide 435 446 (2.5 ) Oncology U.S. 1,175 962 22.1 International 1,839 1,556 18.2 Worldwide 3,013 2,518 19.7 DARZALEX ® U.S. 463 352 31.8 International 474 277 70.9 Worldwide 937 629 49.0 ERLEADA ® U.S. 119 58 * International 24 3 * Worldwide 143 61 * IMBRUVICA ® U.S. 432 349 23.9 International 599 435 37.8 Worldwide 1,031 784 31.6 VELCADE ® U.S. — — — International 108 263 (59.0 ) Worldwide 108 263 (59.0 ) ZYTIGA ® / abiraterone acetate U.S. 139 185 (25.2 ) International 552 494 11.7 Worldwide 690 679 1.6 OTHER ONCOLOGY U.S. 22 18 20.1 International 82 84 (2.7) Worldwide 104 102 1.3 Pulmonary Hypertension U.S. 486 430 13.0 International 260 226 14.9 Worldwide 745 656 13.7 OPSUMIT ® U.S. 229 172 33.0 International 160 133 20.2 Worldwide 389 306 27.4 UPTRAVI ® U.S. 212 176 20.7 International 38 22 70.2 Worldwide 250 198 26.2 OTHER PULMONARY HYPERTENSION U.S. 44 82 (45.9) International 62 71 (12.4) Worldwide 106 152 (30.4) Cardiovascular / Metabolism / Other U.S. 806 947 (14.9 ) International 354 398 (11.0 ) Worldwide 1,160 1,345 (13.8 ) XARELTO ® U.S. 527 542 (2.7 ) International — — — Worldwide 527 542 (2.7 ) INVOKANA ® / INVOKAMET ® U.S. 117 154 (23.6 ) International 58 49 18.6 Worldwide 175 202 (13.5 ) PROCRIT ® / EPREX ® U.S. 76 148 (48.5 ) International 79 78 0.4 Worldwide 155 226 (31.6 ) OTHER U.S. 85 104 (18.0 ) International 217 271 (19.7 ) Worldwide 302 374 (19.2 ) TOTAL PHARMACEUTICAL U.S. 6,061 5,582 8.6 International 5,073 4,662 8.8 Worldwide 11,134 10,244 8.7 MEDICAL DEVICES Interventional Solutions U.S. 365 343 6.6 International 362 389 (6.9 ) Worldwide 727 732 (0.6 ) Orthopaedics U.S. 1,250 1,318 (5.2 ) International 788 885 (11.0 ) Worldwide 2,038 2,204 (7.5 ) HIPS U.S. 206 213 (3.6 ) International 132 148 (11.2 ) Worldwide 337 361 (6.7 ) KNEES U.S. 214 223 (4.2 ) International 130 146 (11.4 ) Worldwide 343 369 (7.0 ) TRAUMA U.S. 407 417 (2.3 ) International 247 268 (8.0 ) Worldwide 654 685 (4.5 ) SPINE, SPORTS & OTHER U.S. 423 465 (8.9 ) International 280 323 (13.3 ) Worldwide 703 788 (10.7 ) Surgery U.S. 844 1,001 (15.7 ) International 1,257 1,394 (9.8 ) Worldwide 2,100 2,395 (12.3 ) ADVANCED U.S. 381 404 (5.7 ) International 567 576 (1.6 ) Worldwide 948 980 (3.3 ) GENERAL U.S. 463 597 (22.5 ) International 690 818 (15.7 ) Worldwide 1,153 1,414 (18.5 ) Vision U.S. 439 446 (1.6 ) International 628 682 (8.0 ) Worldwide 1,067 1,129 (5.5 ) CONTACT LENSES / OTHER U.S. 346 321 7.7 International 467 502 (7.0 ) Worldwide 814 824 (1.3 ) SURGICAL U.S. 93 125 (25.5 ) International 160 180 (11.0 ) Worldwide 253 305 (16.9 ) TOTAL MEDICAL DEVICES U.S. 2,898 3,109 (6.8 ) International 3,034 3,350 (9.4 ) Worldwide 5,932 6,459 (8.2 ) WORLDWIDE U.S. 10,699 10,129 5.6 International 9,992 9,892 1.0 Worldwide $ 20,691 20,021 3.3 % *Percentage greater than 100% or not meaningful
Operating Profit by Segment of Business	EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT Fiscal First Quarter Ended (Dollars in Millions) March 29, March 31, Percent Change Consumer Health (1) $ 770 741 3.9 % Pharmaceutical (2) 3,834 2,331 64.5 Medical Devices (3) 2,025 1,497 35.3 Segment earnings before provision for taxes 6,629 4,569 45.1 Less: Expense not allocated to segments (4) 120 147 Worldwide income before tax $ 6,509 4,422 47.2 % (1) Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (DR. CI: LABO) in the fiscal first quarter of 2019. Includes amortization expense of $0.1 billion in both the fiscal first quarters of 2020 and 2019, respectively. (2) Includes an in-process research and development expense of $0.9 billion related to the Alios asset in the fiscal first quarter of 2019. Includes litigation expense of $0.1 billion and $0.3 billion in the fiscal first quarter of 2020 and 2019, respectively. Includes an unrealized loss on securities of $0.3 billion in the fiscal first quarter of 2020 and an unrealized gain on securities of $0.1 billion in the fiscal first quarter of 2019. Additionally, the fiscal first quarter of 2019 includes a research and development expense of $0.3 billion for an upfront payment related to argenx. Includes amortization expense of $0.8 billion in both the fiscal first quarters of 2020 and 2019. (3) Includes a contingent consideration reversal of $1.0 billion in the fiscal first quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. Includes litigation expense of $0.1 billion in the fiscal first quarter of 2019. Includes a restructuring related charge of $0.1 billion and amortization expense of $0.2 billion in both the fiscal first quarters of 2020 and 2019. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	SALES BY GEOGRAPHIC AREA Fiscal First Quarter Ended (Dollars in Millions) March 29, 2020 March 31, 2019 Percent Change United States $ 10,699 10,129 5.6 % Europe 4,827 4,609 4.7 Western Hemisphere, excluding U.S. 1,502 1,503 (0.1 ) Asia-Pacific, Africa 3,663 3,780 (3.1 ) Total $ 20,691 20,021 3.3 %

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 29, 2020
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve	The following table summarizes the severance related reserves and the associated spending through the fiscal first quarter of 2020: (Dollars in Millions) Severance Asset Write-offs Other (2) Total Reserve balance, December 29, 2019 $ 164 — 16 180 Current year activity: Charges — 11 107 118 Cash payments (6 ) — (99 ) (105 ) Settled non cash — (11 ) (17 ) (3) (28 ) Reserve balance, March 29, 2020 (1) $ 158 — 7 165 (1) Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Relates to pension related actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration. The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Mar. 29, 2020	Dec. 29, 2019
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 1,213	$ 1,117
Goods in process	2,252	1,832
Finished goods	5,403	6,071
Total inventories	$ 8,868	$ 9,020

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	Mar. 29, 2020	Dec. 29, 2019
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	$ 12,625	$ 11,569
Total intangible assets - net	47,338	47,643
Trademarks
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	6,829	6,922
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	5,796	4,647
Patents And Trademarks
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	36,214	36,634
Less accumulated amortization	13,857	13,154
Finite-Lived Intangible Assets, Net	22,357	23,480
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	22,084	22,056
Less accumulated amortization	9,728	9,462
Finite-Lived Intangible Assets, Net	$ 12,356	$ 12,594

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill By Segment (Details) $ in Millions	3 Months Ended
	Mar. 29, 2020USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 33,639
Goodwill, related to acquisitions	157
Currency translation/Other	(325)
Goodwill End of Period	33,471
Consumer Health
Goodwill [Roll Forward]
Goodwill Beginning of Period	9,736
Goodwill, related to acquisitions	0
Currency translation/Other	(223)
Goodwill End of Period	9,513
PHARMACEUTICAL
Goodwill [Roll Forward]
Goodwill Beginning of Period	9,169
Goodwill, related to acquisitions	1
Currency translation/Other	(96)
Goodwill End of Period	9,074
Medical Devices
Goodwill [Roll Forward]
Goodwill Beginning of Period	14,734
Goodwill, related to acquisitions	156
Currency translation/Other	(6)
Goodwill End of Period	$ 14,884

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019	Dec. 29, 2019
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 12,625		$ 11,569
Intangible Assets and Goodwill (Textuals)
Amortization expense of amortizable intangible assets	$ 1,100	$ 1,100
Patents And Trademarks
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life	12 years
Customer relationships and other intangible assets
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life	21 years
Purchased In-Process Research And Development
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 5,796		$ 4,647
Purchased In-Process Research And Development | bermekimab
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	800
Purchased In-Process Research And Development | Verb Surgical Inc.
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 400

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details) $ in Millions	Mar. 29, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 4,500
2021	4,300
2022	4,100
2023	4,100
2024	$ 4,000

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 29, 2020	Mar. 31, 2019	Dec. 29, 2019
Derivative [Line Items]
Available-for-sale Securities, Equity Securities	$ 826		$ 1,148
Accumulated other comprehensive income on derivatives, after tax	$ 675
Reclassification of foreign exchange contracts into earnings, period	next 12 months
Maximum length of time for hedge exposure	18 months
Unrealized gains on equity investments	$ 2	$ 0
Weighted average interest rate on non-current debt	3.26%
Excess of the estimated fair value over the carrying value of debt			3,000
Reversal of contingent consideration	$ 977	(32)
Forward foreign exchange contracts
Derivative [Line Items]
Collateral Already Posted, Aggregate Fair Value	2,000
Derivative, Notional Amount	44,000		45,300
Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Notional Amount	20,100		20,100
Interest Rate Contract
Derivative [Line Items]
Derivative Asset, Noncurrent			$ 1
Equity Investments without readily determinable value | Equity Securities
Derivative [Line Items]
Equity, Fair Value Adjustment, Impairment Loss	33
Other (income) expense
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Fair Value Hedging [Member] | Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Fair Value Hedging [Member] | Cost of Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Fair Value Hedging [Member] | Research and Development Expense [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Fair Value Hedging [Member] | Interest Income Expense Net Member | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	40	38
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	40	38
Fair Value Hedging [Member] | Other (income) expense | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Cash Flow Hedging [Member] | Sales [Member] | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	9	(21)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	11	(6)
Cash Flow Hedging [Member] | Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Cash Flow Hedging [Member] | Cost of Sales [Member] | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(173)	(35)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	302	(296)
Cash Flow Hedging [Member] | Cost of Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Cash Flow Hedging [Member] | Research and Development Expense [Member] | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(110)	(139)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	(110)	(110)
Cash Flow Hedging [Member] | Research and Development Expense [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Cash Flow Hedging [Member] | Interest Income Expense Net Member | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Cash Flow Hedging [Member] | Interest Income Expense Net Member | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	98	55
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	625	59
Cash Flow Hedging [Member] | Other (income) expense | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(2)	6
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	(36)	(13)
Cash Flow Hedging [Member] | Other (income) expense | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019	Dec. 29, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 784		$ 1,715
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income	(138)	$ (96)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	832	(302)
Forward foreign exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Collateral Already Posted, Aggregate Fair Value	2,000
Derivative, Notional Amount	44,000		45,300
Cross currency interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	20,100		$ 20,100
Fair Value Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0
Unrealized gain (loss) arising during period	0	0
Fair Value Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0
Unrealized gain (loss) arising during period	0	0
Fair Value Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0
Unrealized gain (loss) arising during period	0	0
Fair Value Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0
Unrealized gain (loss) arising during period	0	0
Fair Value Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	40	38
Unrealized gain (loss) arising during period	40	38
Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	11	(6)
Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	302	(296)
Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(110)	(110)
Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(36)	(13)
Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	$ 625	$ 59

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheet (Details) - USD ($) $ in Millions	Mar. 29, 2020	Dec. 29, 2019
Fair Value Disclosures [Abstract]
Business Combination, Contingent Consideration, Liability	$ 784	$ 1,715
Carrying Amount of the Hedged Liability	$ 352	$ 66

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019	Dec. 29, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 784		$ 1,715
Not Designated as Hedging Instrument | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Income on Derivative	$ 89	$ (38)

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019	Dec. 29, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 784		$ 1,715
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax	46	$ 71
Sale of Subsidiary Gain (Loss)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Other Income Expense Net
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Cross Currency Interest Rate Contract
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax	$ 827	$ 370

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Dec. 29, 2019
Other Investment Not Readily Marketable [Line Items]
Business Combination, Contingent Consideration, Liability	$ 784	$ 1,715
Equity Investment [Roll Forward]
Non Current Other Assets	5,042	$ 5,695
Equity Securities | Equity Investments with readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	1,148
Changes in Fair Value Reflected in Net Income	(327)
Sales/ Purchases/Other	5
Carrying value, end of period	826
Non Current Other Assets	826
Equity Securities | Equity Investments without readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	712
Changes in Fair Value Reflected in Net Income	(33)
Sales/ Purchases/Other	15
Carrying value, end of period	694
Non Current Other Assets	$ 694

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019	Dec. 29, 2019	Apr. 01, 2019
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$ 2,510
Derivatives designated as hedging instruments : Liabilities	777
Available-for-sale Securities, Equity Securities	826		$ 1,148
Available-for-sale Securities	5,673		4,368
Total Gross Assets	2,630		925
Credit Support Agreement (CSA)	(2,530)		(841)
Total Net Asset	100		84
Total Gross Liabilities	883		652
Credit Support Agreement (CSA)	(531)		(586)
Total Net Liabilities	352		66
Beginning Balance	784	$ 452
Changes in estimated fair value (7)	(977)	32
Additions	106	23
Payments	(60)	0
Ending Balance	1,715	397
Business Combination, Contingent Consideration, Liability	784		1,715
Contingent consideration reversal	(983)	$ 0
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	826		1,148
Available-for-sale Securities	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	2,510		902
Derivatives designated as hedging instruments : Liabilities	777		619
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	5,673
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	0
Business Combination, Contingent Consideration, Liability	784		1,715
Interest Rate Contract
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,569
Derivatives designated as hedging instruments : Liabilities	247
Derivative Assets, Noncurrent			1
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Interest Rate Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,569		693
Derivatives designated as hedging instruments : Liabilities	247		193
Interest Rate Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts
Financial assets and liabilities at fair value
Derivative, Notional Amount	44,000		45,300
Derivatives designated as hedging instruments : Assets	941
Derivatives designated as hedging instruments : Liabilities	530
Derivatives not designated as hedging instruments : Assets	120
Derivatives not designated as hedging instruments : Liabilities	106
Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	941		209
Derivatives designated as hedging instruments : Liabilities	530		426
Derivatives not designated as hedging instruments : Assets	120		23
Derivatives not designated as hedging instruments : Liabilities	106		33
Forward foreign exchange contracts | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Cross currency interest rate swaps
Financial assets and liabilities at fair value
Derivative, Notional Amount	20,100		20,100
Auris Health
Financial assets and liabilities at fair value
Business Combination, Contingent Consideration, Liability	200			$ 2,350
Contingent consideration reversal	(983)
Other Noncurrent Liabilities
Financial assets and liabilities at fair value
Business Combination, Contingent Consideration, Liability	165
Other Noncurrent Liabilities | Auris Health
Financial assets and liabilities at fair value
Business Combination, Contingent Consideration, Liability	759		1,631
Other Current Liabilities
Financial assets and liabilities at fair value
Business Combination, Contingent Consideration, Liability	$ 25		$ 84

Fair Value Measurements - Cash,

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions	Mar. 29, 2020	Dec. 29, 2019
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Estimated Fair Value	$ 5,673	$ 4,368
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	15,530	17,305
Marketable securities	2,494	$ 1,982
Total cash, cash equivalents and current marketable securities, Carrying Amount	18,022
Total cash, cash equivalents and current marketable securities, Unrecognized Gain	5
Total cash, cash equivalents and current marketable securities, Unrecognized Loss	(3)
Total cash, cash equivalents and current marketable securities, Estimated Fair Value	18,024
Held-to-maturity Securities
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	12,351
Held-to-maturity Securities, Unrecognized Gain	1
Held-to-maturity Securities, Unrecognized Loss	(1)
Held-to-maturity Securities - Estimated Fair Value	12,351
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	11,255
Marketable securities	1,096
Held-to-maturity Securities | Cash
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,499
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	2,499
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,499
Held-to-maturity Securities | Non-U.S. sovereign securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	90
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	90
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	90
Marketable securities	0
Held-to-maturity Securities | U.S. reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	3,965
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	3,965
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	3,965
Marketable securities	0
Held-to-maturity Securities | Other reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	473
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	473
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	473
Held-to-maturity Securities | Corporate debt securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,135
Held-to-maturity Securities, Unrecognized Gain	1
Held-to-maturity Securities, Unrecognized Loss	(1)
Held-to-maturity Securities - Estimated Fair Value	2,135
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	1,039
Marketable securities	1,096
Held-to-maturity Securities | Money market funds
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,424
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	2,424
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,424
Held-to-maturity Securities | Time deposits(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	765
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	765
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	765
Available-for-sale Securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	5,671
Available-for-sale Securities, Unrecognized Gain	4
Available-for-sale Securities, Unrecognized Loss	(2)
Available-for-sale Securities - Estimated Fair Value	5,673
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	4,275
Marketable securities	1,398
Available-for-sale Securities | Corporate debt securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	253
Available-for-sale Securities, Unrecognized Gain	0
Available-for-sale Securities, Unrecognized Loss	(2)
Available-for-sale Securities - Estimated Fair Value	251
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	15
Marketable securities	236
Available-for-sale Securities | US Treasury and Government [Member]
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	5,418
Available-for-sale Securities, Unrecognized Gain	4
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	5,422
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	4,260
Marketable securities	$ 1,162

Fair Value Measurements - Sch_4

Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details) $ in Millions	Mar. 29, 2020USD ($)
Cost Basis
Due within one year	$ 5,632
Due after one year through five years	39
Due after five years through ten years	0
Total debt securities	5,671
Fair Value
Due within one year	5,635
Due after one year through five years	38
Due after five years through ten years	0
Total debt securities	$ 5,673

Fair Value Measurements - Fin_2

Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details) - USD ($) $ in Millions	Mar. 29, 2020	Dec. 29, 2019
Financial Liabilities
Current Debt	$ 2,190	$ 1,202
Non-Current Debt
Non-Current Debt	25,393	$ 26,494
Carrying Amount
Financial Liabilities
Current Debt	2,190
Non-Current Debt
Non-Current Debt	25,393
Estimated Fair Value
Financial Liabilities
Current Debt	2,234
Non-Current Debt
Non-Current Debt	$ 29,410
3.55% Notes due 2021
Non-Current Debt
Stated interest rate (as a percent)	3.55%
3.55% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 449
3.55% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 463
2.45% Notes due 2021
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.45% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 350
2.45% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 356
0.250% Notes due 2022 (1B Euro 1.0980)
Non-Current Debt
Stated interest rate (as a percent)	0.25%
0.250% Notes due 2022 (1B Euro 1.0980) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,097
0.250% Notes due 2022 (1B Euro 1.0980) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,096
2.25% Notes due 2022
Non-Current Debt
Stated interest rate (as a percent)	2.25%
2.25% Notes due 2022 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 998
2.25% Notes due 2022 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,019
6.73% Debentures due 2023
Non-Current Debt
Stated interest rate (as a percent)	6.73%
6.73% Debentures due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 250
6.73% Debentures due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 301
3.375% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	3.375%
3.375% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 804
3.375% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 875
2.05% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	2.05%
2.05% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 499
2.05% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 512
0.650% Notes due 2024 (750MM Euro 1.0980)
Non-Current Debt
Stated interest rate (as a percent)	0.65%
0.650% Notes due 2024 (750MM Euro 1.0980) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 821
0.650% Notes due 2024 (750MM Euro 1.0980) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 826
5.50% Notes due 2024 (500 MM GBP 1.2023)
Non-Current Debt
Stated interest rate (as a percent)	5.50%
5.50% Notes due 2024 (500 MM GBP 1.2023) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 597
5.50% Notes due 2024 (500 MM GBP 1.2023) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 697
2.625% Notes due 2025
Non-Current Debt
Stated interest rate (as a percent)	2.625%
2.625% Notes due 2025 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 748
2.625% Notes due 2025 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 796
2.45% Notes due 2026
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.45% Notes due 2026 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,993
2.45% Notes due 2026 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,112
2.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	2.95%
2.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 997
2.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,074
2.90% Notes due 2028
Non-Current Debt
Stated interest rate (as a percent)	2.90%
2.90% Notes due 2028 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,494
2.90% Notes due 2028 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,640
1.150% Notes due 2028 (750MM Euro 1.0980)
Non-Current Debt
Stated interest rate (as a percent)	1.15%
1.150% Notes due 2028 (750MM Euro 1.0980) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 817
1.150% Notes due 2028 (750MM Euro 1.0980) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 833
6.95% Notes due 2029
Non-Current Debt
Stated interest rate (as a percent)	6.95%
6.95% Notes due 2029 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297
6.95% Notes due 2029 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 419
4.95% Debentures due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.95%
4.95% Debentures due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 498
4.95% Debentures due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 661
4.375% Notes due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.375%
4.375% Notes due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 856
4.375% Notes due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,099
1.650% Notes due 2035 (1.5B Euro 1.0980)
Non-Current Debt
Stated interest rate (as a percent)	1.65%
1.650% Notes due 2035 (1.5B Euro 1.0980) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,631
1.650% Notes due 2035 (1.5B Euro 1.0980) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,699
3.55% Notes due 2036
Non-Current Debt
Stated interest rate (as a percent)	3.55%
3.55% Notes due 2036 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 989
3.55% Notes due 2036 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,172
5.95% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	5.95%
5.95% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 992
5.95% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,477
3.625% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	3.625%
3.625% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,487
3.625% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,719
3.40% Notes due 2038
Non-Current Debt
Stated interest rate (as a percent)	3.40%
3.40% Notes due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 991
3.40% Notes due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,144
5.85% Debentures due 2038
Non-Current Debt
Stated interest rate (as a percent)	5.85%
5.85% Debentures due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 696
5.85% Debentures due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,072
4.50% Debentures due 2040
Non-Current Debt
Stated interest rate (as a percent)	4.50%
4.50% Debentures due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 539
4.50% Debentures due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 689
4.85% Notes due 2041
Non-Current Debt
Stated interest rate (as a percent)	4.85%
4.85% Notes due 2041 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297
4.85% Notes due 2041 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 432
4.50% Notes due 2043
Non-Current Debt
Stated interest rate (as a percent)	4.50%
4.50% Notes due 2043 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 495
4.50% Notes due 2043 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 696
3.70% Notes due 2046
Non-Current Debt
Stated interest rate (as a percent)	3.70%
3.70% Notes due 2046 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,973
3.70% Notes due 2046 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,406
3.75% Notes due 2047
Non-Current Debt
Stated interest rate (as a percent)	3.75%
3.75% Notes due 2047 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 991
3.75% Notes due 2047 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,230
3.50% Notes due 2048
Non-Current Debt
Stated interest rate (as a percent)	3.50%
3.50% Notes due 2048 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 742
3.50% Notes due 2048 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	890
Other | Carrying Amount
Non-Current Debt
Non-Current Debt	5
Other | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 5

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Billions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Income Tax (Textuals)
Worldwide effective income tax rate (as a percent)	11.00%	15.20%
Deferred tax asset related to TRAF	$ 0.3
Deferred tax expense related to TRAF	$ 0.2
Net impact to tax rate due to GILTI deferred taxes, percent	1.30%
Net impact to tax rate due to change in contingent consideration liability	1.90%
Unrecognized tax benefits	$ 3.2
Accrued Taxes On Income [Member]
Income Tax (Textuals)
Unrecognized tax benefits	0.2
Internal Revenue Service (IRS) [Member]
Income Tax (Textuals)
Payment on unrecognized tax benefit liability	$ 0.6

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 326	$ 276
Interest cost	240	275
Expected return on plan assets	(614)	(583)
Amortization of prior service cost/(credit)	0	1
Recognized actuarial losses	223	144
Curtailments and settlements	19	(1)
Net periodic benefit cost	194	112
Other Benefit Plans
Components of net periodic benefit cost
Service cost	72	68
Interest cost	33	46
Expected return on plan assets	(2)	(2)
Amortization of prior service cost/(credit)	(8)	(8)
Recognized actuarial losses	36	32
Curtailments and settlements	0	0
Net periodic benefit cost	$ 131	$ 136

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans (Details) $ in Millions	3 Months Ended
	Mar. 29, 2020USD ($)
U.S.
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 23
International retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 9

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	$ 59,471	$ 59,752
Net change	(352)	(295)
Ending Balance	61,294	58,955
Accumulated Foreign Currency Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(8,705)
Net change	(1,519)
Ending Balance	(10,224)
Accumulated Net Investment Gain (Loss) Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	0
Net change	2
Ending Balance	2
Accumulated Defined Benefit Plans Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(6,891)
Net change	195
Ending Balance	(6,696)
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(295)
Net change	970
Ending Balance	675
AOCI Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(15,891)	(15,222)
Net change	(352)	(295)
Ending Balance	$ (16,243)	$ (15,517)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share	$ 2.20	$ 1.41
Average shares outstanding — basic	2,633,700,000	2,660,800,000
Potential shares exercisable under stock option plans	126,000,000	136,700,000
Less: shares which could be repurchased under treasury stock method	(89,400,000)	(99,400,000)
Convertible debt shares	700,000	700,000
Average shares outstanding — diluted	2,671,000,000	2,698,800,000
Diluted net earnings per share	$ 2.17	$ 1.39
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,000,000	0

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Sales by segment of business
Sales to customers	$ 20,691	$ 20,021
Percent Change (as a percent)	3.30%
U.S.
Sales by segment of business
Sales to customers	$ 10,699	10,129
Percent Change (as a percent)	5.60%
International
Sales by segment of business
Sales to customers	$ 9,992	9,892
Percent Change (as a percent)	1.00%
Consumer Health
Sales by segment of business
Sales to customers	$ 3,625	3,318
Percent Change (as a percent)	9.20%
Consumer Health | U.S.
Sales by segment of business
Sales to customers	$ 1,740	1,438
Percent Change (as a percent)	21.00%
Consumer Health | International
Sales by segment of business
Sales to customers	$ 1,885	1,880
Percent Change (as a percent)	0.30%
Consumer Health | Baby Care
Sales by segment of business
Sales to customers	$ 361	394
Percent Change (as a percent)	(8.20%)
Consumer Health | Baby Care | U.S.
Sales by segment of business
Sales to customers	$ 92	87
Percent Change (as a percent)	6.70%
Consumer Health | Baby Care | International
Sales by segment of business
Sales to customers	$ 269	307
Percent Change (as a percent)	(12.40%)
Consumer Health | Skin Health/Beauty
Sales by segment of business
Sales to customers	$ 1,117	1,090
Percent Change (as a percent)	2.50%
Consumer Health | Skin Health/Beauty | U.S.
Sales by segment of business
Sales to customers	$ 659	588
Percent Change (as a percent)	12.10%
Consumer Health | Skin Health/Beauty | International
Sales by segment of business
Sales to customers	$ 458	502
Percent Change (as a percent)	(8.80%)
Consumer Health | Oral Care
Sales by segment of business
Sales to customers	$ 395	367
Percent Change (as a percent)	7.60%
Consumer Health | Oral Care | U.S.
Sales by segment of business
Sales to customers	$ 176	151
Percent Change (as a percent)	16.20%
Consumer Health | Oral Care | International
Sales by segment of business
Sales to customers	$ 219	216
Percent Change (as a percent)	1.50%
Consumer Health | OTC
Sales by segment of business
Sales to customers	$ 1,348	1,087
Percent Change (as a percent)	24.10%
Consumer Health | OTC | U.S.
Sales by segment of business
Sales to customers	$ 689	507
Percent Change (as a percent)	35.90%
Consumer Health | OTC | International
Sales by segment of business
Sales to customers	$ 659	580
Percent Change (as a percent)	13.70%
Consumer Health | Women's Health
Sales by segment of business
Sales to customers	$ 232	225
Percent Change (as a percent)	2.90%
Consumer Health | Women's Health | U.S.
Sales by segment of business
Sales to customers	$ 4	3
Percent Change (as a percent)	32.00%
Consumer Health | Women's Health | International
Sales by segment of business
Sales to customers	$ 228	222
Percent Change (as a percent)	2.50%
Consumer Health | Wound Care/Other
Sales by segment of business
Sales to customers	$ 171	155
Percent Change (as a percent)	10.70%
Consumer Health | Wound Care/Other | U.S.
Sales by segment of business
Sales to customers	$ 119	102
Percent Change (as a percent)	17.00%
Consumer Health | Wound Care/Other | International
Sales by segment of business
Sales to customers	$ 52	53
Percent Change (as a percent)	(1.20%)
PHARMACEUTICAL
Sales by segment of business
Sales to customers	$ 11,134	10,244
Percent Change (as a percent)	8.70%
PHARMACEUTICAL | U.S.
Sales by segment of business
Sales to customers	$ 6,061	5,582
Percent Change (as a percent)	8.60%
PHARMACEUTICAL | International
Sales by segment of business
Sales to customers	$ 5,073	4,662
Percent Change (as a percent)	8.80%
PHARMACEUTICAL | Immunology
Sales by segment of business
Sales to customers	$ 3,638	3,251
Percent Change (as a percent)	11.90%
PHARMACEUTICAL | Immunology | U.S.
Sales by segment of business
Sales to customers	$ 2,410	2,163
Percent Change (as a percent)	11.40%
PHARMACEUTICAL | Immunology | International
Sales by segment of business
Sales to customers	$ 1,228	1,088
Percent Change (as a percent)	12.80%
PHARMACEUTICAL | Immunology | REMICADE®
Sales by segment of business
Sales to customers	$ 990	1,102
Percent Change (as a percent)	(10.20%)
PHARMACEUTICAL | Immunology | REMICADE® | U.S.
Sales by segment of business
Sales to customers	$ 625	774
Percent Change (as a percent)	(19.30%)
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports
Sales by segment of business
Sales to customers	$ 110	76
Percent Change (as a percent)	44.30%
PHARMACEUTICAL | Immunology | REMICADE® | International
Sales by segment of business
Sales to customers	$ 256	252
Percent Change (as a percent)	1.50%
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA®
Sales by segment of business
Sales to customers	$ 529	524
Percent Change (as a percent)	1.10%
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S.
Sales by segment of business
Sales to customers	$ 272	263
Percent Change (as a percent)	3.40%
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International
Sales by segment of business
Sales to customers	$ 258	261
Percent Change (as a percent)	(1.20%)
PHARMACEUTICAL | Immunology | STELARA®
Sales by segment of business
Sales to customers	$ 1,819	1,405
Percent Change (as a percent)	29.50%
PHARMACEUTICAL | Immunology | STELARA® | U.S.
Sales by segment of business
Sales to customers	$ 1,217	882
Percent Change (as a percent)	37.90%
PHARMACEUTICAL | Immunology | STELARA® | International
Sales by segment of business
Sales to customers	$ 603	523
Percent Change (as a percent)	15.20%
PHARMACEUTICAL | Immunology | TREMFYA®
Sales by segment of business
Sales to customers	$ 296	217
Percent Change (as a percent)	36.40%
PHARMACEUTICAL | Immunology | TREMFYA® | U.S.
Sales by segment of business
Sales to customers	$ 187	168
Percent Change (as a percent)	11.50%
PHARMACEUTICAL | Immunology | TREMFYA® | International
Sales by segment of business
Sales to customers	$ 109	49
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY
Sales by segment of business
Sales to customers	$ 3	3
Percent Change (as a percent)	(6.90%)
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S.
Sales by segment of business
Sales to customers	$ 0	0
Percent Change (as a percent)	0.00%
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International
Sales by segment of business
Sales to customers	$ 3	3
Percent Change (as a percent)	(6.90%)
PHARMACEUTICAL | Infectious Diseases
Sales by segment of business
Sales to customers	$ 920	846
Percent Change (as a percent)	8.70%
PHARMACEUTICAL | Infectious Diseases | U.S.
Sales by segment of business
Sales to customers	$ 436	357
Percent Change (as a percent)	22.30%
PHARMACEUTICAL | Infectious Diseases | International
Sales by segment of business
Sales to customers	$ 483	489
Percent Change (as a percent)	(1.20%)
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine
Sales by segment of business
Sales to customers	$ 224	211
Percent Change (as a percent)	6.10%
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S.
Sales by segment of business
Sales to customers	$ 12	12
Percent Change (as a percent)	0.60%
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International
Sales by segment of business
Sales to customers	$ 212	199
Percent Change (as a percent)	6.40%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
Sales by segment of business
Sales to customers	$ 579	523
Percent Change (as a percent)	10.80%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S.
Sales by segment of business
Sales to customers	$ 396	315
Percent Change (as a percent)	25.50%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International
Sales by segment of business
Sales to customers	$ 184	208
Percent Change (as a percent)	(11.60%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES
Sales by segment of business
Sales to customers	$ 116	112
Percent Change (as a percent)	4.00%
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S.
Sales by segment of business
Sales to customers	$ 29	30
Percent Change (as a percent)	(3.40%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International
Sales by segment of business
Sales to customers	$ 87	82
Percent Change (as a percent)	6.70%
PHARMACEUTICAL | Neuroscience
Sales by segment of business
Sales to customers	$ 1,658	1,629
Percent Change (as a percent)	1.80%
PHARMACEUTICAL | Neuroscience | U.S.
Sales by segment of business
Sales to customers	$ 748	723
Percent Change (as a percent)	3.30%
PHARMACEUTICAL | Neuroscience | International
Sales by segment of business
Sales to customers	$ 910	905
Percent Change (as a percent)	0.50%
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate
Sales by segment of business
Sales to customers	$ 171	214
Percent Change (as a percent)	(20.10%)
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | U.S.
Sales by segment of business
Sales to customers	$ 52	97
Percent Change (as a percent)	(46.10%)
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | International
Sales by segment of business
Sales to customers	$ 118	116
Percent Change (as a percent)	1.50%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
Sales by segment of business
Sales to customers	$ 883	790
Percent Change (as a percent)	11.70%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | U.S.
Sales by segment of business
Sales to customers	$ 544	483
Percent Change (as a percent)	12.60%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | International
Sales by segment of business
Sales to customers	$ 339	307
Percent Change (as a percent)	10.30%
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA®
Sales by segment of business
Sales to customers	$ 170	179
Percent Change (as a percent)	(5.10%)
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S.
Sales by segment of business
Sales to customers	$ 76	77
Percent Change (as a percent)	(0.30%)
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International
Sales by segment of business
Sales to customers	$ 94	102
Percent Change (as a percent)	(8.70%)
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE
Sales by segment of business
Sales to customers	$ 435	446
Percent Change (as a percent)	(2.50%)
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S.
Sales by segment of business
Sales to customers	$ 75	66
Percent Change (as a percent)	12.50%
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International
Sales by segment of business
Sales to customers	$ 360	379
Percent Change (as a percent)	(5.10%)
PHARMACEUTICAL | Oncology
Sales by segment of business
Sales to customers	$ 3,013	2,518
Percent Change (as a percent)	19.70%
PHARMACEUTICAL | Oncology | U.S.
Sales by segment of business
Sales to customers	$ 1,175	962
Percent Change (as a percent)	22.10%
PHARMACEUTICAL | Oncology | International
Sales by segment of business
Sales to customers	$ 1,839	1,556
Percent Change (as a percent)	18.20%
PHARMACEUTICAL | Oncology | DARZALEX®
Sales by segment of business
Sales to customers	$ 937	629
Percent Change (as a percent)	49.00%
PHARMACEUTICAL | Oncology | DARZALEX® | U.S.
Sales by segment of business
Sales to customers	$ 463	352
Percent Change (as a percent)	31.80%
PHARMACEUTICAL | Oncology | DARZALEX® | International
Sales by segment of business
Sales to customers	$ 474	277
Percent Change (as a percent)	70.90%
PHARMACEUTICAL | Oncology | ERLEADA [Member]
Sales by segment of business
Sales to customers	$ 143	61
PHARMACEUTICAL | Oncology | ERLEADA [Member] | U.S.
Sales by segment of business
Sales to customers	119	58
PHARMACEUTICAL | Oncology | ERLEADA [Member] | International
Sales by segment of business
Sales to customers	24	3
PHARMACEUTICAL | Oncology | IMBRUVICA®
Sales by segment of business
Sales to customers	$ 1,031	784
Percent Change (as a percent)	31.60%
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S.
Sales by segment of business
Sales to customers	$ 432	349
Percent Change (as a percent)	23.90%
PHARMACEUTICAL | Oncology | IMBRUVICA® | International
Sales by segment of business
Sales to customers	$ 599	435
Percent Change (as a percent)	37.80%
PHARMACEUTICAL | Oncology | VELCADE®
Sales by segment of business
Sales to customers	$ 108	263
Percent Change (as a percent)	(59.00%)
PHARMACEUTICAL | Oncology | VELCADE® | U.S.
Sales by segment of business
Sales to customers	$ 0	0
Percent Change (as a percent)	0.00%
PHARMACEUTICAL | Oncology | VELCADE® | International
Sales by segment of business
Sales to customers	$ 108	263
Percent Change (as a percent)	(59.00%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate
Sales by segment of business
Sales to customers	$ 690	679
Percent Change (as a percent)	1.60%
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | U.S.
Sales by segment of business
Sales to customers	$ 139	185
Percent Change (as a percent)	(25.20%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | International
Sales by segment of business
Sales to customers	$ 552	494
Percent Change (as a percent)	11.70%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY
Sales by segment of business
Sales to customers	$ 104	102
Percent Change (as a percent)	1.30%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S.
Sales by segment of business
Sales to customers	$ 22	18
Percent Change (as a percent)	20.10%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International
Sales by segment of business
Sales to customers	$ 82	84
Percent Change (as a percent)	(2.70%)
PHARMACEUTICAL | Pulmonary Hypertension
Sales by segment of business
Sales to customers	$ 745	656
Percent Change (as a percent)	13.70%
PHARMACEUTICAL | Pulmonary Hypertension | U.S.
Sales by segment of business
Sales to customers	$ 486	430
Percent Change (as a percent)	13.00%
PHARMACEUTICAL | Pulmonary Hypertension | International
Sales by segment of business
Sales to customers	$ 260	226
Percent Change (as a percent)	14.90%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT®
Sales by segment of business
Sales to customers	$ 389	306
Percent Change (as a percent)	27.40%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S.
Sales by segment of business
Sales to customers	$ 229	172
Percent Change (as a percent)	33.00%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International
Sales by segment of business
Sales to customers	$ 160	133
Percent Change (as a percent)	20.20%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI®
Sales by segment of business
Sales to customers	$ 250	198
Percent Change (as a percent)	26.20%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S.
Sales by segment of business
Sales to customers	$ 212	176
Percent Change (as a percent)	20.70%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International
Sales by segment of business
Sales to customers	$ 38	22
Percent Change (as a percent)	70.20%
PHARMACEUTICAL | Pulmonary Hypertension | OTHER PULMONARY HYPERTENSION
Sales by segment of business
Sales to customers	$ 106	152
Percent Change (as a percent)	(30.40%)
PHARMACEUTICAL | Pulmonary Hypertension | OTHER PULMONARY HYPERTENSION | U.S.
Sales by segment of business
Sales to customers	$ 44	82
Percent Change (as a percent)	(45.90%)
PHARMACEUTICAL | Pulmonary Hypertension | OTHER PULMONARY HYPERTENSION | International
Sales by segment of business
Sales to customers	$ 62	71
Percent Change (as a percent)	(12.40%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other
Sales by segment of business
Sales to customers	$ 1,160	1,345
Percent Change (as a percent)	(13.80%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S.
Sales by segment of business
Sales to customers	$ 806	947
Percent Change (as a percent)	(14.90%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International
Sales by segment of business
Sales to customers	$ 354	398
Percent Change (as a percent)	(11.00%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO®
Sales by segment of business
Sales to customers	$ 527	542
Percent Change (as a percent)	(2.70%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S.
Sales by segment of business
Sales to customers	$ 527	542
Percent Change (as a percent)	(2.70%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International
Sales by segment of business
Sales to customers	$ 0	0
Percent Change (as a percent)	0.00%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET®
Sales by segment of business
Sales to customers	$ 175	202
Percent Change (as a percent)	(13.50%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S.
Sales by segment of business
Sales to customers	$ 117	154
Percent Change (as a percent)	(23.60%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International
Sales by segment of business
Sales to customers	$ 58	49
Percent Change (as a percent)	18.60%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX®
Sales by segment of business
Sales to customers	$ 155	226
Percent Change (as a percent)	(31.60%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S.
Sales by segment of business
Sales to customers	$ 76	148
Percent Change (as a percent)	(48.50%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International
Sales by segment of business
Sales to customers	$ 79	78
Percent Change (as a percent)	0.40%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER PULMONARY HYPERTENSION
Sales by segment of business
Sales to customers	$ 302	374
Percent Change (as a percent)	(19.20%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER PULMONARY HYPERTENSION | U.S.
Sales by segment of business
Sales to customers	$ 85	104
Percent Change (as a percent)	(18.00%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER PULMONARY HYPERTENSION | International
Sales by segment of business
Sales to customers	$ 217	271
Percent Change (as a percent)	(19.70%)
MEDICAL DEVICES
Sales by segment of business
Sales to customers	$ 5,932	6,459
Percent Change (as a percent)	(8.20%)
MEDICAL DEVICES | U.S.
Sales by segment of business
Sales to customers	$ 2,898	3,109
Percent Change (as a percent)	(6.80%)
MEDICAL DEVICES | International
Sales by segment of business
Sales to customers	$ 3,034	3,350
Percent Change (as a percent)	(9.40%)
MEDICAL DEVICES | Interventional Solutions
Sales by segment of business
Sales to customers	$ 727	732
Percent Change (as a percent)	(0.60%)
MEDICAL DEVICES | Interventional Solutions | U.S.
Sales by segment of business
Sales to customers	$ 365	343
Percent Change (as a percent)	6.60%
MEDICAL DEVICES | Interventional Solutions | International
Sales by segment of business
Sales to customers	$ 362	389
Percent Change (as a percent)	(6.90%)
MEDICAL DEVICES | Orthopaedics
Sales by segment of business
Sales to customers	$ 2,038	2,204
Percent Change (as a percent)	(7.50%)
MEDICAL DEVICES | Orthopaedics | U.S.
Sales by segment of business
Sales to customers	$ 1,250	1,318
Percent Change (as a percent)	(5.20%)
MEDICAL DEVICES | Orthopaedics | International
Sales by segment of business
Sales to customers	$ 788	885
Percent Change (as a percent)	(11.00%)
MEDICAL DEVICES | Orthopaedics | HIPS
Sales by segment of business
Sales to customers	$ 337	361
Percent Change (as a percent)	(6.70%)
MEDICAL DEVICES | Orthopaedics | HIPS | U.S.
Sales by segment of business
Sales to customers	$ 206	213
Percent Change (as a percent)	(3.60%)
MEDICAL DEVICES | Orthopaedics | HIPS | International
Sales by segment of business
Sales to customers	$ 132	148
Percent Change (as a percent)	(11.20%)
MEDICAL DEVICES | Orthopaedics | KNEES
Sales by segment of business
Sales to customers	$ 343	369
Percent Change (as a percent)	(7.00%)
MEDICAL DEVICES | Orthopaedics | KNEES | U.S.
Sales by segment of business
Sales to customers	$ 214	223
Percent Change (as a percent)	(4.20%)
MEDICAL DEVICES | Orthopaedics | KNEES | International
Sales by segment of business
Sales to customers	$ 130	146
Percent Change (as a percent)	(11.40%)
MEDICAL DEVICES | Orthopaedics | TRAUMA
Sales by segment of business
Sales to customers	$ 654	685
Percent Change (as a percent)	(4.50%)
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S.
Sales by segment of business
Sales to customers	$ 407	417
Percent Change (as a percent)	(2.30%)
MEDICAL DEVICES | Orthopaedics | TRAUMA | International
Sales by segment of business
Sales to customers	$ 247	268
Percent Change (as a percent)	(8.00%)
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER
Sales by segment of business
Sales to customers	$ 703	788
Percent Change (as a percent)	(10.70%)
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | U.S.
Sales by segment of business
Sales to customers	$ 423	465
Percent Change (as a percent)	(8.90%)
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | International
Sales by segment of business
Sales to customers	$ 280	323
Percent Change (as a percent)	(13.30%)
MEDICAL DEVICES | Surgery
Sales by segment of business
Sales to customers	$ 2,100	2,395
Percent Change (as a percent)	(12.30%)
MEDICAL DEVICES | Surgery | U.S.
Sales by segment of business
Sales to customers	$ 844	1,001
Percent Change (as a percent)	(15.70%)
MEDICAL DEVICES | Surgery | International
Sales by segment of business
Sales to customers	$ 1,257	1,394
Percent Change (as a percent)	(9.80%)
MEDICAL DEVICES | Surgery | ADVANCED
Sales by segment of business
Sales to customers	$ 948	980
Percent Change (as a percent)	(3.30%)
MEDICAL DEVICES | Surgery | ADVANCED | U.S.
Sales by segment of business
Sales to customers	$ 381	404
Percent Change (as a percent)	(5.70%)
MEDICAL DEVICES | Surgery | ADVANCED | International
Sales by segment of business
Sales to customers	$ 567	576
Percent Change (as a percent)	(1.60%)
MEDICAL DEVICES | Surgery | GENERAL
Sales by segment of business
Sales to customers	$ 1,153	1,414
Percent Change (as a percent)	(18.50%)
MEDICAL DEVICES | Surgery | GENERAL | U.S.
Sales by segment of business
Sales to customers	$ 463	597
Percent Change (as a percent)	(22.50%)
MEDICAL DEVICES | Surgery | GENERAL | International
Sales by segment of business
Sales to customers	$ 690	818
Percent Change (as a percent)	(15.70%)
MEDICAL DEVICES | Vision
Sales by segment of business
Sales to customers	$ 1,067	1,129
Percent Change (as a percent)	(5.50%)
MEDICAL DEVICES | Vision | U.S.
Sales by segment of business
Sales to customers	$ 439	446
Percent Change (as a percent)	(1.60%)
MEDICAL DEVICES | Vision | International
Sales by segment of business
Sales to customers	$ 628	682
Percent Change (as a percent)	(8.00%)
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER
Sales by segment of business
Sales to customers	$ 814	824
Percent Change (as a percent)	(1.30%)
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S.
Sales by segment of business
Sales to customers	$ 346	321
Percent Change (as a percent)	7.70%
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International
Sales by segment of business
Sales to customers	$ 467	502
Percent Change (as a percent)	(7.00%)
MEDICAL DEVICES | Vision | SURGICAL
Sales by segment of business
Sales to customers	$ 253	305
Percent Change (as a percent)	(16.90%)
MEDICAL DEVICES | Vision | SURGICAL | U.S.
Sales by segment of business
Sales to customers	$ 93	125
Percent Change (as a percent)	(25.50%)
MEDICAL DEVICES | Vision | SURGICAL | International
Sales by segment of business
Sales to customers	$ 160	$ 180
Percent Change (as a percent)	(11.00%)

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area	3.30%
Sales to customers	$ 20,691	$ 20,021
Percentage Change in Operating Income Loss	47.20%
Earnings before provision for taxes on income	$ 6,509	4,422
In-process research and development	0	890
Reversal of contingent consideration	983	0
Restructuring charges	58	36
Consumer Health
Segment Reporting Information [Line Items]
Sales to customers	3,625	3,318
PHARMACEUTICAL
Segment Reporting Information [Line Items]
Sales to customers	11,134	10,244
In-process research and development		900
Litigation expense	100	300
Research and Development Expense		300
Medical Devices
Segment Reporting Information [Line Items]
Sales to customers	5,932	6,459
Restructuring charges	100	100
Litigation expense	100
Operating Segments
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 6,629	4,569
Percentage Change in Operating Income Loss	45.10%
Operating Segments | Consumer Health
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 770	741
Percentage Change in Operating Income Loss	3.90%
Amortization	$ 100	100
Operating Segments | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 3,834	2,331
Percentage Change in Operating Income Loss	64.50%
Amortization	$ 800	800
Unrealized Gain (Loss) on Securities	300	100
Operating Segments | Medical Devices
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 2,025	1,497
Percentage Change in Operating Income Loss	35.30%
Amortization	$ 200	200
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Total Segment Operating Income	120	147
Ci:z Holdings Co. Ltd. | Consumer Health
Segment Reporting Information [Line Items]
Gain on sale of equity investments		300
Auris Health
Segment Reporting Information [Line Items]
Reversal of contingent consideration	$ 983
United States
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area	5.60%
Sales to customers	$ 10,699	10,129
United States | Consumer Health
Segment Reporting Information [Line Items]
Sales to customers	1,740	1,438
United States | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Sales to customers	6,061	5,582
United States | Medical Devices
Segment Reporting Information [Line Items]
Sales to customers	$ 2,898	3,109
Europe
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area	4.70%
Sales to customers	$ 4,827	4,609
Western Hemisphere, excluding U.S.
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area	(0.10%)
Sales to customers	$ 1,502	1,503
Asia-Pacific, Africa
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area	(3.10%)
Sales to customers	$ 3,663	$ 3,780
Other Income | Auris Health
Segment Reporting Information [Line Items]
Reversal of contingent consideration	$ 1,000

Segments of Business and Geog_5

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Sales by geographic area
Sales	$ 20,691	$ 20,021
Percentage Change In Sales By Geographic Area	3.30%
United States
Sales by geographic area
Sales	$ 10,699	10,129
Percentage Change In Sales By Geographic Area	5.60%
Europe
Sales by geographic area
Sales	$ 4,827	4,609
Percentage Change In Sales By Geographic Area	4.70%
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,502	1,503
Percentage Change In Sales By Geographic Area	(0.10%)
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 3,663	$ 3,780
Percentage Change In Sales By Geographic Area	(3.10%)

Business Combinations and Div_2

Business Combinations and Divestitures - Narrative (Details) $ in Millions, ¥ in Billions	Apr. 01, 2019USD ($)	Jan. 17, 2019USD ($)	Jan. 17, 2019JPY (¥)	Mar. 29, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 29, 2019USD ($)	Jan. 16, 2019
Business Acquisition [Line Items]
Payments to acquire businesses				$ 939	$ 1,683
Goodwill				33,471		$ 33,639
Contingent consideration				784		$ 1,715
Reversal of contingent consideration				983	0
Other (income) expense, net				679	22
bermekimab
Business Acquisition [Line Items]
Payments to acquire businesses				800
Intangible assets				800
Verb Surgical Inc.
Business Acquisition [Line Items]
Intangible assets				400
Goodwill				200
Other assets				200
Liabilities assumed				300
Fair value of previously held equity investment				400
Auris Health
Business Acquisition [Line Items]
Payments to acquire businesses	$ 3,400
Intangible assets	3,000
Goodwill	2,000
Liabilities assumed	1,800
Contingent consideration	2,350			200
Marketable securities	$ 200
Reversal of contingent consideration				983
Ci:z Holdings Co. Ltd.
Business Acquisition [Line Items]
Intangible assets				1,500
Goodwill				1,200
Liabilities assumed				400
Business acquisition cost		$ 2,100	¥ 230
Foreign exchange rate							109.06
Other (income) expense, net					$ 300
Adjustments made to intangible assets				$ 100
Weighted average useful life				15 years 3 months 18 days
Discontinued Operations, Held-for-sale or Disposed of by Sale | Supply Chain
Business Acquisition [Line Items]
Assets held for sale, current				$ 100
Other Income | Auris Health
Business Acquisition [Line Items]
Reversal of contingent consideration				$ 1,000

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions	1 Months Ended	3 Months Ended
	Jan. 31, 2020USD ($)	Mar. 29, 2020USD ($)patientclaimant	Dec. 29, 2019USD ($)claimant	Oct. 31, 2019USD ($)
ASR
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		940
Pinnacle Acetabular Cup System
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		9,500
Pelvic Meshes
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		16,500
Risperdal
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		10,900
XARELTO®
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		24,600
Talc
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		19,400
Invokana
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		300
Physiomesh
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		3,500
Opioid
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			2,900
Judicial Ruling
Legal Proceeding (Textuals)
Loss Contingency, Damages Awarded, Value | $	$ 6.8	$ 344	$ 8,000
Pending Litigation
Legal Proceeding (Textuals)
Loss Contingency, Estimate of Possible Loss | $				$ 4,000
DePuy ASR U.S. | settled litigation
Legal Proceeding (Textuals)
Number of patients in settlement | patient		10,000
Oklahoma Attorney General vs. Johnson & Johnson and JPI | settled litigation
Legal Proceeding (Textuals)
Loss Contingency, Damages Awarded, Value | $		$ 465
Oklahoma Attorney General vs. Johnson & Johnson and JPI | Judicial Ruling
Legal Proceeding (Textuals)
Loss Contingency, Damages Awarded, Value | $		572
Damages from Product Defects | Baby Powder | Judicial Ruling
Legal Proceeding (Textuals)
Litigation contingency | $		$ 4,700

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 58	$ 36
Supply Chain
Restructuring Cost and Reserve [Line Items]
Restructuring charges	118
Restructuring charges recorded to date	1,000
Supply Chain | Restructuring Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	58
Supply Chain | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	15
Supply Chain | Other (income) expense
Restructuring Cost and Reserve [Line Items]
Restructuring charges	45
Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	1,900
Cost savings expected	600
Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	2,300
Cost savings expected	800
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges	118
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 100	$ 100
Medical Devices | Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Period for activity	4 years
Medical Devices | Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Period for activity	5 years

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 58	$ 36
Period of cash outlays for severance expected to be paid out	2 years
Medical Devices
Restructuring Reserve [Roll Forward]
Reserve balance beginning	$ 180
Restructuring charges	118
Payments for Restructuring	(105)
Restructuring Reserve, Settled without Cash	(28)
Reserve balance ending	165
Medical Devices | Employee Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning	164
Restructuring charges	0
Payments for Restructuring	(6)
Restructuring Reserve, Settled without Cash	0
Reserve balance ending	158
Medical Devices | Asset Write-off
Restructuring Reserve [Roll Forward]
Reserve balance beginning	0
Restructuring charges	11
Payments for Restructuring	0
Restructuring Reserve, Settled without Cash	(11)
Reserve balance ending	0
Medical Devices | Other Restructuring
Restructuring Reserve [Roll Forward]
Reserve balance beginning	16
Restructuring charges	107
Payments for Restructuring	(99)
Restructuring Reserve, Settled without Cash	(17)
Reserve balance ending	$ 7